

# CPC COOPERATIVE PATENT CLASSIFICATION

## C CHEMISTRY; METALLURGY

(NOTES omitted)

### CHEMISTRY

## C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

## C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

### NOTES

1. Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.
2. Attention is drawn to Notes (1) to (3) following the title of Class [C12](#).
3. When classifying in this group, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.

### WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

<a href="#">C12N 1/11</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/13</a>	covered by	<a href="#">C12N 15/79</a>
<a href="#">C12N 1/15</a>	covered by	<a href="#">C12N 15/80</a>
<a href="#">C12N 1/19</a>	covered by	<a href="#">C12N 15/81</a>
<a href="#">C12N 1/21</a>	covered by	<a href="#">C12N 15/74</a>
<a href="#">C12N 5/02</a>	covered by	<a href="#">C12N 5/0006</a> , <a href="#">C12N 5/04</a> - <a href="#">C12N 5/166</a>
<a href="#">C12N 5/07</a> - <a href="#">C12N 5/095</a>	covered by	<a href="#">C12N 5/06</a>
<a href="#">C12N 5/18</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/20</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/22</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 5/24</a>	covered by	<a href="#">C12N 5/163</a>
<a href="#">C12N 5/26</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 5/28</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 15/53</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 7/01</a>	covered by	<a href="#">C12N 7/00</a>
<a href="#">C12N 9/02</a> - <a href="#">C12N 9/08</a>	covered by	<a href="#">C12N 9/0004</a>
<a href="#">C12N 9/26</a>	covered by	<a href="#">C12N 9/2408</a>
<a href="#">C12N 9/28</a> - <a href="#">C12N 9/30</a>	covered by	<a href="#">C12N 9/2414</a> - <a href="#">C12N 9/242</a>
<a href="#">C12N 9/32</a>	covered by	<a href="#">C12N 9/2422</a>
<a href="#">C12N 9/34</a>	covered by	<a href="#">C12N 9/2428</a>
<a href="#">C12N 9/36</a>	covered by	<a href="#">C12N 9/2462</a>
<a href="#">C12N 9/38</a>	covered by	<a href="#">C12N 9/2468</a>
<a href="#">C12N 9/40</a>	covered by	<a href="#">C12N 9/2465</a>
<a href="#">C12N 9/42</a>	covered by	<a href="#">C12N 9/2434</a>
<a href="#">C12N 9/44</a>	covered by	<a href="#">C12N 9/2451</a>
<a href="#">C12N 9/46</a>	covered by	<a href="#">C12N 9/2454</a>
<a href="#">C12N 9/56</a>	covered by	<a href="#">C12N 9/54</a>
<a href="#">C12N 9/66</a>	covered by	<a href="#">C12N 9/6448</a>
<a href="#">C12N 9/68</a>	covered by	<a href="#">C12N 9/6435</a>
<a href="#">C12N 9/70</a>	covered by	<a href="#">C07K 14/3153</a>
<a href="#">C12N 9/72</a>	covered by	<a href="#">C12N 9/6462</a>
<a href="#">C12N 9/74</a>	covered by	<a href="#">C12N 9/6429</a>
<a href="#">C12N 9/76</a>	covered by	<a href="#">C12N 9/6427</a>
<a href="#">C12N 15/05</a>	covered by	<a href="#">C12N 5/14</a>
<a href="#">C12N 15/06</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 15/07</a>	covered by	<a href="#">C12N 5/16</a>
<a href="#">C12N 15/08</a>	covered by	<a href="#">C12N 5/166</a>
<a href="#">C12N 15/12</a>	covered by	<a href="#">C07K 14/435</a>

## C12N

### C12N

(continued)

C12N 15/13	covered by	<a href="#">C07K 16/00</a>
C12N 15/14	covered by	<a href="#">C07K 14/765</a>
C12N 15/15	covered by	<a href="#">C07K 14/81</a>
C12N 15/16	covered by	<a href="#">C07K 14/575</a>
C12N 15/17	covered by	<a href="#">C07K 14/62</a>
C12N 15/18	covered by	<a href="#">C07K 14/61</a>
C12N 15/19	covered by	<a href="#">C07K 14/52</a>
C12N 15/20	covered by	<a href="#">C07K 14/555</a>
C12N 15/21	covered by	<a href="#">C07K 14/56</a>
C12N 15/22	covered by	<a href="#">C07K 14/565</a>
C12N 15/23	covered by	<a href="#">C07K 14/57</a>
C12N 15/24	covered by	<a href="#">C07K 14/54</a>
C12N 15/25	covered by	<a href="#">C07K 14/545</a>
C12N 15/26	covered by	<a href="#">C07K 14/55</a>
C12N 15/27	covered by	<a href="#">C07K 14/53</a>
C12N 15/28	covered by	<a href="#">C07K 14/525</a>
C12N 15/29	covered by	<a href="#">C07K 14/415</a>
C12N 15/30	covered by	<a href="#">C07K 14/44</a>
C12N 15/31	covered by	<a href="#">C07K 14/195</a> , <a href="#">C07K 14/005</a>
C12N 15/32	covered by	<a href="#">C07K 14/325</a>
C12N 15/33	covered by	<a href="#">C07K 14/005</a>
C12N 15/34	covered by	<a href="#">C07K 14/01</a>
C12N 15/35	covered by	<a href="#">C07K 14/015</a>
C12N 15/36	covered by	<a href="#">C07K 14/02</a>
C12N 15/37	covered by	<a href="#">C07K 14/025</a>
C12N 15/38	covered by	<a href="#">C07K 14/03</a>
C12N 15/39	covered by	<a href="#">C07K 14/065</a>
C12N 15/40	covered by	<a href="#">C07K 14/08</a>
C12N 15/41	covered by	<a href="#">C07K 14/085</a>
C12N 15/42	covered by	<a href="#">C07K 14/09</a>
C12N 15/43	covered by	<a href="#">C07K 14/105</a>
C12N 15/44	covered by	<a href="#">C07K 14/11</a>
C12N 15/45	covered by	<a href="#">C07K 14/115</a>
C12N 15/46	covered by	<a href="#">C07K 14/14</a>
C12N 15/47	covered by	<a href="#">C07K 14/145</a>
C12N 15/48	covered by	<a href="#">C07K 14/15</a>
C12N 15/49	covered by	<a href="#">C07K 14/155</a>
C12N 15/50	covered by	<a href="#">C07K 14/165</a>
C12N 15/51	covered by	<a href="#">C07K 14/02</a> , <a href="#">C07K 14/10</a> , <a href="#">C07K 14/18</a>
C12N 15/53	covered by	<a href="#">C12N 9/0004</a>
C12N 15/54	covered by	<a href="#">C12N 9/10</a>
C12N 15/55	covered by	<a href="#">C12N 9/14</a>
C12N 15/56	covered by	<a href="#">C12N 9/24</a>
C12N 15/57	covered by	<a href="#">C12N 9/48</a>
C12N 15/58	covered by	<a href="#">C12N 9/6456</a>
C12N 15/59	covered by	<a href="#">C12N 9/6483</a>
C12N 15/60	covered by	<a href="#">C12N 9/88</a>
C12N 15/61	covered by	<a href="#">C12N 9/90</a>
C12N 15/83	covered by	<a href="#">C12N 15/82</a>
C12N 15/84	covered by	<a href="#">C12N 15/82</a>

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

1/00	<b>Microorganisms, e.g. protozoa; Compositions thereof (medicinal preparations containing material from microorganisms <a href="#">A61K 35/66</a>; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines <a href="#">A61K 39/00</a>); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor</b>	1/04	• Preserving or maintaining viable microorganisms (immobilised microorganisms <a href="#">C12N 11/00</a> )
		1/06	• Lysis of microorganisms
		1/063	• • {of yeast}
		1/066	• • {by physical methods}
		1/08	• Reducing the nucleic acid content
		1/10	• Protozoa; Culture media therefor
		1/12	• Unicellular algae; Culture media therefor (as new plants <a href="#">A01H 13/00</a> )
1/005	• {after treatment of microbial biomass not covered by <a href="#">C12N 1/02</a> - <a href="#">C12N 1/08</a> }	1/14	• Fungi (culture of mushrooms <a href="#">A01G 18/00</a> ; as new plants per se <a href="#">A01H 15/00</a> {; fungi per se <a href="#">C12R 1/645</a> - <a href="#">C12R 1/885</a> }); Culture media therefor
1/02	• Separating microorganisms from their culture media		

- 1/16 . . Yeasts; Culture media therefor
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/20 . Bacteria {(bacteria per se [C12R 1/01](#) - [C12R 1/64](#))}; Culture media therefor
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C<sub>1</sub> to C<sub>6</sub>
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)

### 3/00 Spore forming or isolating processes

### 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques [A01H 4/00](#))

#### NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage;
- "progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.

- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}

#### WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)

- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}

#### NOTE

In this group, the following words are used with the meanings indicated:

- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
- a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
- a "multipotent" cell is restricted to one lineage.

"Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

#### NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 . . . . {Whole embryos; Culture medium therefor}
- 5/0605 . . . . {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 . . . . {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0608 . . . {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#))}
- 5/0609 . . . . {Oocytes, oogonia (fertilised oocytes [C12N 5/0604](#))}
- 5/061 . . . . {Sperm cells, spermatogonia}

5/0611	. . . . {Primordial germ cells, e.g. embryonic germ cells [EG]}	5/0652	. . . . {Cells of skeletal and connective tissues; Mesenchyme}
5/0612	. . . . {sorting of gametes, e.g. according to sex or motility}	5/0653	. . . . {Adipocytes; Adipose tissue}
5/0613	. . . . {Cells from endocrine organs ( <a href="#">pancreas C12N 5/0676</a> , <a href="#">gonads C12N 5/0681</a> )}	5/0654	. . . . {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
5/0614	. . . . {Adrenal gland}	5/0655	. . . . {Chondrocytes; Cartilage}
5/0615	. . . . {Pineal gland}	5/0656	. . . . {Adult fibroblasts}
5/0616	. . . . {Pituitary gland}	5/0657	. . . . {Cardiomyocytes; Heart cells}
5/0617	. . . . {Thyroid and parathyroid glands}	5/0658	. . . . {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts}
5/0618	. . . . {Cells of the nervous system}	5/0659	. . . . . {Satellite cells}
5/0619	. . . . {Neurons}	5/066	. . . . {Tenocytes; Tendons, Ligaments}
5/062	. . . . {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}	5/0661	. . . . {Smooth muscle cells}
5/0621	. . . . {Eye cells, e.g. cornea, iris pigmented cells ( <a href="#">photoreceptors C12N 5/062</a> )}	5/0662	. . . . {Stem cells}
5/0622	. . . . {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}	5/0663	. . . . . {Bone marrow mesenchymal stem cells (BM-MSC)}
5/0623	. . . . {Stem cells}	5/0664	. . . . . {Dental pulp stem cells, Dental follicle stem cells}
5/0625	. . . . {Epidermal cells, skin cells; Cells of the oral mucosa}	5/0665	. . . . . {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood}
5/0626	. . . . {Melanocytes}	5/0666	. . . . . {Mesenchymal stem cells from hair follicles}
5/0627	. . . . {Hair cells}	5/0667	. . . . . {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
5/0628	. . . . . {Hair stem cells; Hair progenitors ( <a href="#">mesenchymal stem cells from hair follicles C12N 5/0666</a> )}	5/0668	. . . . . {Mesenchymal stem cells from other natural sources}
5/0629	. . . . {Keratinocytes; Whole skin}	5/0669	. . . . . {Bone marrow stromal cells; Whole bone marrow ( <a href="#">isolated stem cells from bone marrow C12N 5/0647</a> , <a href="#">C12N 5/0663</a> )}
5/063	. . . . . {Keratinocyte stem cells; Keratinocyte progenitors}	5/067	. . . . {Hepatocytes}
5/0631	. . . . {Mammary cells}	5/0671	. . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
5/0632	. . . . {Cells of the oral mucosa}	5/0672	. . . . {Stem cells; Progenitor cells; Precursor cells; Oval cells}
5/0633	. . . . {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrimal glands}	5/0676	. . . . {Pancreatic cells}
5/0634	. . . . {Cells from the blood or the immune system}	5/0677	. . . . . {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
<b><u>NOTE</u></b>		5/0678	. . . . . {Stem cells; Progenitor cells; Precursor cells}
Committed progenitors are classified with their progeny		5/0679	. . . . {Cells of the gastro-intestinal tract}
5/0635	. . . . {B lymphocytes}	5/068	. . . . {Stem cells; Progenitors}
5/0636	. . . . {T lymphocytes}	5/0681	. . . . {Cells of the genital tract; Non-germinal cells from gonads}
5/0637	. . . . . {Immunosuppressive T lymphocytes, e.g. regulatory T cells (Treg)}	5/0682	. . . . . {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells ( <a href="#">oocytes C12N 5/0609</a> )}
5/0638	. . . . . {Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]}	5/0683	. . . . . {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells ( <a href="#">spermatogonia C12N 5/061</a> )}
5/0639	. . . . . {Dendritic cells, e.g. Langerhans cells in the epidermis}	5/0684	. . . . {Cells of the urinary tract or kidneys}
5/064	. . . . . {Immunosuppressive dendritic cells}	5/0685	. . . . {Bladder epithelial cells}
5/0641	. . . . {Erythrocytes}	5/0686	. . . . {Kidney cells}
5/0642	. . . . {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells}	5/0687	. . . . {Renal stem cells; Renal progenitors}
5/0643	. . . . {Osteoclasts}	5/0688	. . . . {Cells from the lungs or the respiratory tract}
5/0644	. . . . {Platelets; Megakaryocytes}	5/0689	. . . . {Stem cells; Progenitors}
5/0645	. . . . {Macrophages, e.g. Kuepfer cells in the liver; Monocytes}	5/069	. . . . {Vascular Endothelial cells}
5/0646	. . . . {Natural killers cells [NK], NKT cells}	5/0691	. . . . . {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels}
5/0647	. . . . {Haematopoietic stem cells; Uncommitted or multipotent progenitors}	5/0692	. . . . {Stem cells; Progenitor cells; Precursor cells}
5/0648	. . . . {Splenocytes}	5/0693	. . . . {Tumour cells; Cancer cells}
5/065	. . . . {Thymocytes}		
5/0651	. . . . {Lymph nodes}		

- 5/0694 . . . . {Cells of blood, e.g. leukemia cells, myeloma cells}
- 5/0695 . . . . {Stem cells; Progenitor cells; Precursor cells}
- 5/0696 . . . {Artificially induced pluripotent stem cells, e.g. iPS}
- 5/0697 . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents ([blood vessels C12N 5/0691](#))}
- 5/0698 . . . {Skin equivalents}
- 5/10 . Cells modified by introduction of foreign genetic material
- 5/12 . . Fused cells, e.g. hybridomas
- 5/14 . . . Plant cells
- 5/16 . . . Animal cells
- 5/163 . . . . {one of the fusion partners being a B or a T lymphocyte}
- 5/166 . . . . {resulting from interspecies fusion}
- 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof ([preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K 39/00](#))**
- WARNING**
- From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).
- 7/02 . Recovery or purification
- 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- 7/04 . Inactivation or attenuation; Producing viral sub-units
- 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- 7/06 . . {Inactivation or attenuation} by chemical treatment
- 7/08 . . {Inactivation or attenuation} by serial passage of virus
- 9/00 Enzymes; Proenzymes; Compositions thereof ([preparations containing enzymes for cleaning teeth A61K 8/66, A61Q 11/00](#); [medicinal preparations containing enzymes or proenzymes A61K 38/43](#); [enzyme containing detergent compositions C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); **Processes for preparing, activating, inhibiting, separating or purifying enzymes** ([preparation of malt C12C 1/00](#))**
- NOTE**
- Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.
- 9/0002 . {Antibodies with enzymatic activity, e.g. abzymes}
- 9/0004 . {Oxidoreductases (1.)}
- 9/0006 . . {acting on CH-OH groups as donors (1.1)}
- 9/0008 . . {acting on the aldehyde or oxo group of donors (1.2)}
- 9/001 . . {acting on the CH-CH group of donors (1.3)}
- 9/0012 . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
- 9/0014 . . . {acting on the CH-NH<sub>2</sub> group of donors (1.4)}
- 9/0016 . . . . {with NAD or NADP as acceptor (1.4.1)}
- 9/0018 . . . . . {Phenylalanine dehydrogenase (1.4.1.20)}
- 9/002 . . . . {with a cytochrome as acceptor (1.4.2)}
- 9/0022 . . . . {with oxygen as acceptor (1.4.3)}
- 9/0024 . . . . . {D-Amino acid oxidase (1.4.3.3)}
- 9/0026 . . . {acting on CH-NH groups of donors (1.5)}
- 9/0028 . . . . {with NAD or NADP as acceptor (1.5.1)}
- 9/003 . . . . . {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- 9/0032 . . . . {with oxygen as acceptor (1.5.3)}
- 9/0034 . . . . . {Sarcosine oxidase (1.5.3.1)}
- 9/0036 . . . {acting on NADH or NADPH (1.6)}
- 9/0038 . . . . {with a heme protein as acceptor (1.6.2)}
- 9/004 . . . . . {Cytochrome-b5 reductase (1.6.2.2)}
- 9/0042 . . . . . {NADPH-cytochrome P450 reductase (1.6.2.4)}
- 9/0044 . . . {acting on other nitrogen compounds as donors (1.7)}
- 9/0046 . . . . {with oxygen as acceptor (1.7.3)}
- 9/0048 . . . . . {Uricase (1.7.3.3)}
- 9/0051 . . {acting on a sulfur group of donors (1.8)}
- 9/0053 . . {acting on a heme group of donors (1.9)}
- 9/0055 . . {acting on diphenols and related substances as donors (1.10)}
- 9/0057 . . . {with oxygen as acceptor (1.10.3)}
- 9/0059 . . . . {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
- 9/0061 . . . . {Laccase (1.10.3.2)}
- 9/0063 . . . . {Ascorbate oxidase (1.10.3.3)}
- 9/0065 . . {acting on hydrogen peroxide as acceptor (1.11)}
- 9/0067 . . {acting on hydrogen as donor (1.12)}
- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 . . . . {Nitric-oxide synthase (1.14.13.39)}
- 9/0077 . . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
- 9/0079 . . . . {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
- 9/0081 . . . . {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
- 9/0083 . . . {Miscellaneous (1.14.99)}
- 9/0085 . . . . {Steroid 17 alpha-monooxygenase (1.14.99.9)}
- 9/0087 . . . . {Steroid 21-monooxygenase (1.14.99.10)}
- 9/0089 . . {acting on superoxide as acceptor (1.15)}
- 9/0091 . . {oxidizing metal ions (1.16)}
- 9/0093 . . {acting on CH or CH<sub>2</sub> groups (1.17)}
- 9/0095 . . {acting on iron-sulfur proteins as donor (1.18)}
- 9/0097 . . {acting on reduced flavodoxin as donor (1.19)}
- 9/10 . Transferases (2.) ([ribonucleases C12N 9/22](#))
- 9/1003 . . {transferring one-carbon groups (2.1)}
- 9/1007 . . . {Methyltransferases (general) (2.1.1.)}
- 9/1011 . . . . {Catechol O-methyltransferase (2.1.1.6)}
- 9/1014 . . . {Hydroxymethyl-, formyl-transferases (2.1.2)}
- 9/1018 . . . {Carboxy- and carbamoyl transferases (2.1.3)}



9/1022	. . {transferring aldehyde or ketonic groups (2.2)}	9/18	. . . Carboxylic ester hydrolases {(3.1.1)}
9/1025	. . {Acyltransferases (2.3)}	9/20	. . . . Triglyceride splitting, e.g. by means of lipase
9/1029	. . . {transferring groups other than amino-acyl groups (2.3.1)}	9/22	. . . Ribonucleases {RNases, DNases (catalytic nucleic acids C12N 15/113)}
9/1033	. . . . {Chloramphenicol O-acetyltransferase (2.3.1.28)}	9/24	. . acting on glycosyl compounds (3.2)
9/1037	. . . . {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}	9/2402	. . . {hydrolysing O- and S- glycosyl compounds (3.2.1)}
9/104	. . . {Aminoacyltransferases (2.3.2)}	9/2405	. . . . {Glucanases}
9/1044	. . . . {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII}	9/2408	. . . . . {acting on alpha -1,4-glucosidic bonds}
9/1048	. . {Glycosyltransferases (2.4)}	9/2411	. . . . . {Amylases}
9/1051	. . . {Hexosyltransferases (2.4.1)}	9/2414	. . . . . . {Alpha-amylase (3.2.1.1.)}
9/1055	. . . . {Levansucrase (2.4.1.10)}	9/2417	. . . . . . . {from microbiological source}
9/1059	. . . . {Cellulose synthases (2.4.1.12; 2.4.1.29)}	9/242	. . . . . . . {Fungal source}
9/1062	. . . . {Sucrose synthase (2.4.1.13)}	9/2422	. . . . . . . {from plant source}
9/1066	. . . . {Sucrose phosphate synthase (2.4.1.14)}	9/2425	. . . . . . . {Beta-amylase (3.2.1.2)}
9/107	. . . . {1,4-Alpha-glucan branching enzyme (2.4.1.18)}	9/2428	. . . . . . . {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase}
9/1074	. . . . {Cyclomaltodextrin glucanotransferase (2.4.1.19)}	9/2431	. . . . . . . {Beta-fructofuranosidase (3.2.1.26), i.e. invertase}
9/1077	. . . {Pentosyltransferases (2.4.2)}	9/2434	. . . . . . . {acting on beta-1,4-glucosidic bonds}
9/1081	. . . {transferring other glycosyl groups (2.4.99)}	9/2437	. . . . . . . {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)}
9/1085	. . {transferring alkyl or aryl groups other than methyl groups (2.5)}	9/244	. . . . . . . {Endo-1,3(4)-beta-glucanase (3.2.1.6)}
9/1088	. . . {Glutathione transferase (2.5.1.18)}	9/2442	. . . . . . . {Chitinase (3.2.1.14)}
9/1092	. . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase}	9/2445	. . . . . . . {Beta-glucosidase (3.2.1.21)}
9/1096	. . {transferring nitrogenous groups (2.6)}	9/2448	. . . . . . . {Licheninase (3.2.1.73)}
9/12	. . transferring phosphorus containing groups, e.g. kinases (2.7)	9/2451	. . . . . . . {acting on alpha-1,6-glucosidic bonds}
9/1205	. . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}	9/2454	. . . . . . . {Dextranase (3.2.1.11)}
9/1211	. . . . {Thymidine kinase (2.7.1.21)}	9/2457	. . . . . . . {Pullulanase (3.2.1.41)}
9/1217	. . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)}	9/246	. . . . . . . {Isoamylase (3.2.1.68)}
9/1223	. . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)}	9/2462	. . . . . . . {Lysozyme (3.2.1.17)}
9/1229	. . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)}	9/2465	. . . . . . . {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)}
9/1235	. . . {Diphosphotransferases (2.7.6)}	9/2468	. . . . . . . {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)}
9/1241	. . . {Nucleotidyltransferases (2.7.7)}	9/2471	. . . . . . . {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase}
9/1247	. . . . {DNA-directed RNA polymerase (2.7.7.6)}	9/2474	. . . . . . . {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase}
9/1252	. . . . {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}	9/2477	. . . . . . . {Hemicellulases not provided in a preceding group}
9/1258	. . . . {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase}	9/248	. . . . . . . {Xylanases}
9/1264	. . . . {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase}	9/2482	. . . . . . . {Endo-1,4-beta-xylanase (3.2.1.8)}
9/127	. . . . {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase}	9/2485	. . . . . . . {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase}
9/1276	. . . . {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}	9/2488	. . . . . . . {Mannanases}
9/1282	. . . . {RNA uridylyltransferase (2.7.7.52)}	9/2491	. . . . . . . {Beta-mannosidase (3.2.1.25), i.e. mannanase}
9/1288	. . . {Transferases for other substituted phosphate groups (2.7.8)}	9/2494	. . . . . . . {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase}
9/1294	. . . {Phosphotransferases with paired acceptors (2.7.9)}	9/2497	. . . {hydrolysing N- glycosyl compounds (3.2.2)}
9/13	. . {transferring sulfur containing groups (2.8)}	9/48	. . acting on peptide bonds (3.4)
9/14	. Hydrolases (3)	9/485	. . . {Exopeptidases (3.4.11-3.4.19)}
9/16	. . acting on ester bonds (3.1)		

9/50 . . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}

#### **WARNING**

Group [C12N 9/50](#) is impacted by reclassification into group [C12N 9/52](#).

Groups [C12N 9/50](#) and [C12N 9/52](#) should be considered in order to perform a complete search.

9/503 . . . . {derived from viruses}

9/506 . . . . {derived from RNA viruses}

9/52 . . . . derived from bacteria {or Archaea}

#### **NOTE**

{In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.}

#### **WARNING**

Group [C12N 9/52](#) is incomplete pending reclassification of documents from group [C12N 9/50](#).

Groups [C12N 9/50](#) and [C12N 9/52](#) should be considered in order to perform a complete search.

9/54 . . . . bacteria being Bacillus

9/58 . . . . derived from fungi

9/60 . . . . from yeast

9/62 . . . . from Aspergillus

9/63 . . . . {derived from plants}

9/64 . . . . derived from animal tissue

9/6402 . . . . {from non-mammals}

9/6405 . . . . {not being snakes}

9/6408 . . . . {Serine endopeptidases (3.4.21)}

9/641 . . . . {Cysteine endopeptidases (3.4.22)}

9/6413 . . . . {Aspartic endopeptidases (3.4.23)}

9/6416 . . . . {Metalloendopeptidases (3.4.24)}

9/6418 . . . . {from snakes}

9/6421 . . . . {from mammals}

9/6424 . . . . {Serine endopeptidases (3.4.21)}

9/6427 . . . . {Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)}

9/6429 . . . . {Thrombin (3.4.21.5)}

9/6432 . . . . {Coagulation factor Xa (3.4.21.6)}

9/6435 . . . . {Plasmin (3.4.21.7), i.e. fibrinolysin}

9/6437 . . . . {Coagulation factor VIIa (3.4.21.21)}

9/644 . . . . {Coagulation factor IXa (3.4.21.22)}

9/6443 . . . . {Coagulation factor XIa (3.4.21.27)}

9/6445 . . . . {Kallikreins (3.4.21.34; 3.4.21.35)}

9/6448 . . . . {Elastases, e.g. pancreatic elastase (3.4.21.36); leukocyte elastase (3.4.31.37)}

9/6451 . . . . {Coagulation factor XIIIa (3.4.21.38)}

9/6454 . . . . {Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases}

9/6456 . . . . {Plasminogen activators}

9/6459 . . . . {t-plasminogen activator (3.4.21.68), i.e. tPA}

9/6462 . . . . {u-Plasminogen activator (3.4.21.73), i.e. urokinase}

9/6464 . . . . {Protein C (3.4.21.69)}

9/6467 . . . . {Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)}

9/647 . . . . {Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups}

9/6472 . . . . {Cysteine endopeptidases (3.4.22)}

9/6475 . . . . {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}

9/6478 . . . . {Aspartic endopeptidases (3.4.23)}

9/6481 . . . . {Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)}

9/6483 . . . . {Chymosin (3.4.23.4), i.e. rennin}

9/6486 . . . . {Renin (3.4.23.15)}

9/6489 . . . . {Metalloendopeptidases (3.4.24)}

9/6491 . . . . {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}

9/6494 . . . . {Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11}

9/6497 . . . . {Endothelin-converting enzyme (3.4.24.71)}

9/78 . . acting on carbon to nitrogen bonds other than peptide bonds (3.5)

9/80 . . . acting on amide bonds in linear amides {(3.5.1)}

9/82 . . . . Asparaginase {(3.5.1.1)}

9/84 . . . . Penicillin amidase {(3.5.1.11)}

9/86 . . . acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}

9/88 . Lyases (4.)

9/90 . Isomerases (5.)

9/92 . . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}

9/93 . {Ligases (6)}

9/94 . Pancreatin

9/96 . Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

9/98 . Preparation of granular or free-flowing enzyme compositions ([C12N 9/96 takes precedence](#))

9/99 . Enzyme inactivation by chemical treatment

#### **11/00 Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof**

11/02 . Enzymes or microbial cells immobilised on or in an organic carrier

11/04 . . entrapped within the carrier, e.g. gel or hollow fibres

11/06 . . attached to the carrier via a bridging agent

11/08 . . the carrier being a synthetic polymer

#### **WARNING**

Group [C12N 11/08](#) is impacted by reclassification into groups [C12N 11/082](#), [C12N 11/084](#), [C12N 11/087](#), [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#), [C12N 11/096](#), and [C12N 11/098](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 11/082 . . . obtained by reactions only involving carbon-to-carbon unsaturated bonds
- WARNING**
- Groups [C12N 11/082](#), [C12N 11/084](#), and [C12N 11/087](#) are incomplete pending reclassification of documents from group [C12N 11/08](#).
- Groups [C12N 11/08](#), [C12N 11/082](#), [C12N 11/084](#) and [C12N 11/087](#) should be considered in order to perform a complete search.
- 11/084 . . . . Polymers containing vinyl alcohol units
- 11/087 . . . . Acrylic polymers
- 11/089 . . . obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- WARNING**
- Groups [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#) and [C12N 11/096](#) are incomplete pending reclassification of documents from group [C12N 11/08](#).
- Groups [C12N 11/08](#), [C12N 11/089](#), [C12N 11/091](#), [C12N 11/093](#) and [C12N 11/096](#) should be considered in order to perform a complete search.
- 11/091 . . . . Phenol resins; Amino resins
- 11/093 . . . . Polyurethanes
- 11/096 . . . . Polyesters; Polyamides
- 11/098 . . . formed in the presence of the enzymes or microbial cells
- WARNING**
- Group [C12N 11/098](#) is incomplete pending reclassification of documents from group [C12N 11/08](#).
- Groups [C12N 11/08](#) and [C12N 11/098](#) should be considered in order to perform a complete search.
- 11/10 . . the carrier being a carbohydrate
- 11/12 . . . Cellulose or derivatives thereof
- 11/14 . Enzymes or microbial cells immobilised on or in an inorganic carrier
- 11/16 . Enzymes or microbial cells immobilised on or in a biological cell
- 11/18 . Multi-enzyme systems
- 13/00 Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves**
- 15/00 Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se [C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se [A01H](#); plant reproduction by tissue culture techniques [A01H 4/00](#); new animals per se [A01K 67/00](#); use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy [A61K 48/00](#))**
- 15/01 . Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
- 15/02 . Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion {(monoclonal antibodies [C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- 15/03 . . Bacteria
- 15/04 . . Fungi
- 15/09 . Recombinant DNA-technology
- 15/10 . . Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA [C07H 21/00](#); preparation of non-structural polynucleotides from microorganisms or with enzymes [C12P 19/34](#))
- NOTE**
- After the symbol [C12N 15/10](#) - [C12N 15/1096](#), and separated therefrom by a + sign, it is desirable to add the indexing codes selected from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention. When more than one indexing code is selected, the different codes are separated by a + sign. Example : [C12N 15/1037](#) + [C12Q 2537/125](#) + [C12Q 2521/537](#)
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 . . . . {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 . . . . . {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 . . . . . {by using magnetic beads}
- 15/1017 . . . . {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 . . . . {*In vivo* mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 . . . . {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 . . . . {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 . . . . {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 . . . . {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 . . . . {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 . . . . {SELEX}
- 15/1051 . . . . {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 . . . . {Protein x Protein interaction, e.g. two hybrid selection}



- 15/1058 . . . . {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 . . . . {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 . . . . {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 . . . . {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 . . . . {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 . . . . {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 . . . . {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays [C12N 15/1086](#))}
- 15/1082 . . . . {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 . . . . {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 . . . . {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 . . . . {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 . . . {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, [C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
- Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 . . . {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 . . . Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants [C12N 15/8218](#))}
- 15/1131 . . . . {against viruses}
- 15/1132 . . . . {against retroviridae, e.g. HIV}
- 15/1133 . . . . {against herpesviridae, e.g. HSV}
- 15/1135 . . . . {against oncogenes or tumor suppressor genes}
- 15/1136 . . . . {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 . . . . {against enzymes (viral enzymes [C12N 15/1131](#); receptors [C12N 15/1138](#))}
- 15/1138 . . . . {against receptors or cell surface proteins}
- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {}; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.
- 15/62 . . . DNA sequences coding for fusion proteins
- NOTE**
- In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.
- 15/625 . . . . {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- 15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))
- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- NOTE**
- In this group, the following expression is used with the meaning indicated:

## C12N

C12N 15/66  
(continued)

- "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.

- 15/67 . . . General methods for enhancing the expression  
15/68 . . . . Stabilisation of the vector  
15/69 . . . . Increasing the copy number of the vector  
15/70 . . . Vectors or expression systems specially adapted for E. coli

### NOTES

1. This group covers the use of E. coli as host.
2. Shuttle vectors also replicating in E. coli are classified according to the other host.

- 15/71 . . . . Expression systems using regulatory sequences derived from the trp-operon  
15/72 . . . . Expression systems using regulatory sequences derived from the lac-operon  
15/73 . . . . Expression systems using phage (lambda) regulatory sequences  
15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

### NOTE

This group covers the use of prokaryotes as hosts.

- 15/743 . . . . {for Agrobacterium; Rhizobium; Bradyrhizobium}  
15/746 . . . . {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}  
15/75 . . . . for Bacillus  
15/76 . . . . for Actinomyces; for Streptomyces  
15/77 . . . . for Corynebacterium; for Brevibacterium  
15/78 . . . . for Pseudomonas  
15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts

### NOTE

This group covers the use of eukaryotes as hosts.

- 15/80 . . . . for fungi  
15/81 . . . . . for yeasts  
15/815 . . . . . {for yeasts other than Saccharomyces}  
15/82 . . . . for plant cells {, e.g. plant artificial chromosomes (PACs)}

### WARNING

Documents are being continuously reclassified into this new classification scheme. See Warning notes below

- 15/8201 . . . . {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}  
15/8202 . . . . . {by biological means, e.g. cell mediated or natural vector}  
15/8203 . . . . . {Virus mediated transformation}

- 15/8205 . . . . . {Agrobacterium mediated transformation}  
15/8206 . . . . . {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated}  
15/8207 . . . . . {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers}  
15/8209 . . . . . {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers}

### NOTE

Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in [C12N 15/8209](#)

- 15/821 . . . . . {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers}  
15/8212 . . . . . {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid}  
15/8213 . . . . . {Targeted insertion of genes into the plant genome by homologous recombination}  
15/8214 . . . . . {Plastid transformation}  
15/8216 . . . . . {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}  
15/8217 . . . . . {Gene switch}  
15/8218 . . . . . {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]}  
15/822 . . . . . {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression}  
15/8221 . . . . . {Transit peptides}  
15/8222 . . . . . {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation}  
15/8223 . . . . . {Vegetative tissue-specific promoters}  
15/8225 . . . . . {Leaf-specific, e.g. including petioles, stomata}  
15/8226 . . . . . {Stem-specific, e.g. including tubers, beets}  
15/8227 . . . . . {Root-specific}  
15/8229 . . . . . {Meristem-specific, e.g. nodal, apical}  
15/823 . . . . . {Reproductive tissue-specific promoters}  
15/8231 . . . . . {Male-specific, e.g. anther, tapetum, pollen}  
15/8233 . . . . . {Female-specific, e.g. pistil, ovule}  
15/8234 . . . . . {Seed-specific, e.g. embryo, endosperm}  
15/8235 . . . . . {Fruit-specific}  
15/8237 . . . . . {Externally regulated expression systems}

15/8238	. . . . .	{chemically inducible, e.g. tetracycline}
15/8239	. . . . .	{pathogen inducible}
15/8241	. . . . .	{Phenotypically and genetically modified plants via recombinant DNA technology}
15/8242	. . . . .	{with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits}
15/8243	. . . . .	{involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine}
15/8245	. . . . .	{involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis}
15/8246	. . . . .	{Non-starch polysaccharides, e.g. cellulose, fructans, levans}
15/8247	. . . . .	{involving modified lipid metabolism, e.g. seed oil composition}
15/8249	. . . . .	{involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life}
15/825	. . . . .	{involving pigment biosynthesis}
<b>NOTE</b>		
Transgenic plants with altered flower morphology are also classified in this group		
15/8251	. . . . .	{Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis}
15/8253	. . . . .	{Methionine or cysteine}
15/8254	. . . . .	{Tryptophan or lysine}
15/8255	. . . . .	{involving lignin biosynthesis}
15/8257	. . . . .	{for the production of primary gene products, e.g. pharmaceutical products, interferon}
15/8258	. . . . .	{for the production of oral vaccines (antigens) or immunoglobulins}
15/8259	. . . . .	{Phytoremediation}
15/8261	. . . . .	{with agronomic (input) traits, e.g. crop yield}
15/8262	. . . . .	{involving plant development}
15/8263	. . . . .	{Ablation; Apoptosis}
15/8265	. . . . .	{Transgene containment, e.g. gene dispersal}
15/8266	. . . . .	{Abscission; Dehiscence; Senescence}
15/8267	. . . . .	{Seed dormancy, germination or sprouting}
15/8269	. . . . .	{Photosynthesis}
15/827	. . . . .	{Flower development or morphology, e.g. flowering promoting factor [FPF]}
15/8271	. . . . .	{for stress resistance, e.g. heavy metal resistance}
15/8273	. . . . .	{for drought, cold, salt resistance}
15/8274	. . . . .	{for herbicide resistance}
15/8275	. . . . .	{Glyphosate}
15/8277	. . . . .	{Phosphinotricin}
15/8278	. . . . .	{Sulfonylurea}

15/8279	. . . . .	{for biotic stress resistance, pathogen resistance, disease resistance}
15/8281	. . . . .	{for bacterial resistance}
15/8282	. . . . .	{for fungal resistance}
15/8283	. . . . .	{for virus resistance}
15/8285	. . . . .	{for nematode resistance}
15/8286	. . . . .	{for insect resistance}
15/8287	. . . . .	{for fertility modification, e.g. apomixis}
15/8289	. . . . .	{Male sterility}
15/829	. . . . .	{Female sterility}
15/8291	. . . . .	{Hormone-influenced development}
15/8293	. . . . .	{Absciscic acid [ABA]}
15/8294	. . . . .	{Auxins}
15/8295	. . . . .	{Cytokinins}
15/8297	. . . . .	{Gibberellins; GA3}
15/8298	. . . . .	{Brassinosteroids}
15/85	. . . . .	for animal cells
15/8509	. . . . .	{for producing genetically modified animals, e.g. transgenic}

**NOTE**

Additional aspects of the modified animals are classified in the groups [A01K 2207/00](#) - [A01K 2267/00](#)

2015/8518	. . . . .	{expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
2015/8527	. . . . .	{for producing animal models, e.g. for tests or diseases}
2015/8536	. . . . .	{Animal models for genetic diseases}
2015/8545	. . . . .	{for Alzheimer's disease}
2015/8554	. . . . .	{Invertebrates models for Alzheimer's disease}
2015/8563	. . . . .	{for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
2015/8572	. . . . .	{Animal models for proliferative diseases, e.g. comprising an oncogene}
2015/8581	. . . . .	{Animal models for infectious diseases, e.g. AIDS}
2015/859	. . . . .	{Animal models comprising reporter system for screening tests}
15/86	. . . . .	<b>Viral vectors</b>
<b>WARNING</b>		
From March 15, 2012 groups <a href="#">C12N 15/861</a> - <a href="#">C12N 15/869</a> and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range <a href="#">C12N 2710/00</a> - <a href="#">C12N 2795/00</a>		
15/861	. . . . .	Adenoviral vectors
15/8613	. . . . .	{Chimaeric vector systems comprising heterologous sequences for production of another viral vector}
15/8616	. . . . .	{Special methods for targeting systems}

15/863	. . . . . Poxviral vectors, {e.g. entomopoxvirus}	2310/14	. . . interfering N.A.
15/8633	. . . . . {Avian poxviral vectors}	2310/141	. . . MicroRNAs, miRNAs
15/8636	. . . . . {Vaccinia virus vectors}	2310/15	. . . Nucleic acids forming more than 2 strands, e.g. TFOs
15/864	. . . . . Parvoviral vectors {, e.g. parvovirus, densovirus}	2310/151	. . . more than 3 strands, e.g. tetrads, H-DNA
15/8645	. . . . . {Adeno-associated virus}	2310/152	. . . on a single-stranded target, e.g. fold-back TFOs
15/866	. . . . . Baculoviral vectors	2310/153	. . . with the aid of a protein, e.g. recombinase
15/867	. . . . . Retroviral vectors	2310/16	. . . Aptamers
15/8673	. . . . . {Special methods for packaging systems}	2310/17	. . . Immunomodulatory nucleic acids
15/8676	. . . . . {Special methods for targeting systems}	2310/18	. . . acting by a non-sequence specific mechanism (other than C12N 2310/16 or C12N 2310/17)
15/869	. . . . . Herpesviral vectors	2310/20	. . . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
15/8695	. . . . . {Herpes simplex virus-based vectors}	2310/30	. . . Chemical structure
15/87	. . . Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation	2310/31	. . . of the backbone
15/873	. . . Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos	2310/311	. . . Phosphotriesters
15/877	. . . Techniques for producing new mammalian cloned embryos	2310/312	. . . Phosphonates
15/8771	. . . . . {Bovine embryos}	2310/3125	. . . . Methylphosphonates
15/8772	. . . . . {Caprine embryos}	2310/313	. . . Phosphorodithioates
15/8773	. . . . . {Ovine embryos}	2310/314	. . . Phosphoramidates
15/8775	. . . . . {Murine embryos}	2310/3145	. . . . with the nitrogen in 3' or 5'-position
15/8776	. . . . . {Primate embryos}	2310/315	. . . Phosphorothioates
15/8777	. . . . . {Rabbit embryos}	2310/316	. . . Phosphonothioates
15/8778	. . . . . {Swine embryos}	2310/317	. . . with an inverted bond, e.g. a cap structure
15/88	. . . using microencapsulation, e.g. using {amphiphile} liposome vesicle	2310/318	. . . where the PO <sub>2</sub> is completely replaced, e.g. MMI or formacetal
15/89	. . . using microinjection	2310/3181	. . . . Peptide nucleic acid, PNA
15/895	. . . {using biolistic methods}	2310/3183	. . . . Diol linkers, e.g. glycols or propanediols
15/90	. . . Stable introduction of foreign DNA into chromosome	2310/319	. . . linked by 2'-5' linkages, i.e. having a free 3'-position
15/902	. . . . {using homologous recombination}	2310/32	. . . of the sugar
15/905	. . . . {in yeast}	2310/321	. . . 2'-O-R Modification
15/907	. . . . {in mammalian cells}	2310/322	. . . 2'-R Modification
2303/00	<b>Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids</b>	2310/323	. . . modified ring structure
	<b>NOTE</b>	2310/3231	. . . . having an additional ring, e.g. LNA, ENA
	Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111	2310/3233	. . . . Morpholino-type ring
2310/00	<b>Structure or type of the nucleic acid</b>	2310/3235	. . . . having the O of the ribose replaced by another atom
2310/10	. . . Type of nucleic acid	2310/33	. . . of the base
2310/11	. . . Antisense	2310/331	. . . Universal or degenerate base
2310/111	. . . spanning the whole gene, or a large part of it	2310/332	. . . Abasic residue
2310/113	. . . targeting other non-coding nucleic acids, e.g. antagomirs	2310/333	. . . Modified A
2310/12	. . . catalytic nucleic acids, e.g. ribozymes	2310/334	. . . Modified C
2310/121	. . . Hammerhead	2310/3341	. . . . 5-Methylcytosine
2310/122	. . . Hairpin	2310/335	. . . Modified T or U
2310/123	. . . Hepatitis delta	2310/336	. . . Modified G
2310/124	. . . based on group I or II introns	2310/337	. . . in alpha-anomeric form
2310/1241	. . . . Tetrahymena	2310/34	. . . Spatial arrangement of the modifications
2310/126	. . . involving RNase P	2310/341	. . . Gapmers, i.e. of the type =====
2310/127	. . . DNazymes	2310/342	. . . Hemimers, i.e. of the type =====
2310/128	. . . processing or releasing ribozyme	2310/343	. . . having patterns, e.g. =====
2310/13	. . . Decoys	2310/344	. . . Position-specific modifications, e.g. on every purine, at the 3'-end
		2310/345	. . . having at least two different backbone modifications
		2310/346	. . . having a combination of backbone and sugar modifications
		2310/35	. . . Nature of the modification
		2310/351	. . . Conjugate
		2310/3511	. . . . intercalating or cleaving agent
		2310/3513	. . . . Protein; Peptide
		2310/3515	. . . . Lipophilic moiety, e.g. cholesterol



- 2310/3517 . . . . Marker; Tag
- 2310/3519 . . . . Fusion with another nucleic acid
- 2310/352 . . . linked to the nucleic acid via a carbon atom
- 2310/3521 . . . . Methyl
- 2310/3523 . . . . Allyl
- 2310/3525 . . . . MOE, methoxyethoxy
- 2310/3527 . . . . Other alkyl chain
- 2310/3529 . . . . Aromatic substituent
- 2310/353 . . . linked to the nucleic acid via an atom other than carbon
- 2310/3531 . . . . Hydrogen
- 2310/3533 . . . . Halogen
- 2310/3535 . . . . Nitrogen
- 2310/50 . Physical structure
- 2310/51 . . in polymeric form, e.g. multimers, concatemers
- 2310/52 . . branched
- 2310/53 . . partially self-complementary or closed
- 2310/531 . . . Stem-loop; Hairpin
- 2310/532 . . . Closed or circular
- 2310/533 . . . having a mismatch or nick in at least one of the strands

#### 2320/00 Applications; Uses

- 2320/10 . in screening processes
- 2320/11 . . for the determination of target sites, i.e. of active nucleic acids
- 2320/12 . . in functional genomics, i.e. for the determination of gene function
- 2320/13 . . in a process of directed evolution, e.g. SELEX, acquiring a new function
- 2320/30 . Special therapeutic applications
- 2320/31 . . Combination therapy
- 2320/32 . . Special delivery means, e.g. tissue-specific
- 2320/33 . . Alteration of splicing
- 2320/34 . . Allele or polymorphism specific uses
- 2320/35 . . based on a specific dosage / administration regimen
- 2320/50 . Methods for regulating/modulating their activity
- 2320/51 . . modulating the chemical stability, e.g. nuclease-resistance
- 2320/52 . . modulating the physical stability, e.g. GC-content
- 2320/53 . . reducing unwanted side-effects

#### 2330/00 Production

- 2330/10 . naturally occurring
- 2330/30 . chemically synthesised
- 2330/31 . . Libraries, arrays
- 2330/50 . Biochemical production, i.e. in a transformed host cell
- 2330/51 . . Specially adapted vectors

#### 2500/00 Specific components of cell culture medium

- 2500/02 . Atmosphere, e.g. low oxygen conditions
- 2500/05 . Inorganic components
- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
- 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- 2500/14 . . . . Calcium; Ca chelators; Calcitonin
- 2500/16 . . . . Magnesium; Mg chelators
- 2500/20 . . . Transition metals
- 2500/22 . . . . Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
- 2500/24 . . . . Iron; Fe chelators; Transferrin

- 2500/25 . . . . . Insulin-transferrin; Insulin-transferrin-selenium
- 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
- 2500/32 . . Amino acids
- 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
- 2500/34 . . Sugars
- 2500/35 . . Polyols, e.g. glycerin, inositol
- 2500/36 . . Lipids
- 2500/38 . . Vitamins
- 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
- 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
- 2500/44 . . Thiols, e.g. mercaptoethanol
- 2500/46 . . Amines, e.g. putrescine
- 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
- 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
- 2500/62 . . DMSO
- 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
- 2500/72 . . from bacteria
- 2500/74 . . from fungi, e.g. yeasts
- 2500/76 . . from plants
- 2500/78 . . from protozoa
- 2500/80 . . from animals
- 2500/82 . . . from invertebrates
- 2500/84 . . . from mammals
- 2500/90 . Serum-free medium, which may still contain naturally-sourced components
- 2500/92 . . Medium free of human- or animal-derived components
- 2500/95 . . Protein-free medium and culture conditions
- 2500/98 . Xeno-free medium and culture conditions
- 2500/99 . Serum-free medium

#### WARNING

This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)

#### 2501/00 Active agents used in cell culture processes, e.g. differentiation

#### NOTE

Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.

- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes



2501/03	• Compounds acting on the NO pathway, e.g. nitrososarginine	2501/2314	• • • Interleukin-14 (IL-14)
2501/04	• Immunosuppressors, e.g. cyclosporin, tacrolimus	2501/2315	• • • Interleukin-15 (IL-15)
2501/05	• Adjuvants	2501/2316	• • • Interleukin-16 (IL-16)
2501/051	• • Lipid A (MPA, MPL)	2501/2317	• • • Interleukin-17 (IL-17)
2501/052	• • Lipopolysaccharides [LPS]	2501/2318	• • • Interleukin-18 (IL-18)
2501/054	• • Muramyle peptides	2501/2319	• • • Interleukin-19 (IL-19)
2501/056	• • Immunostimulating oligonucleotides, e.g. CpG	2501/232	• • • Interleukin-20 (IL-20)
2501/06	• Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide	2501/2321	• • • Interleukin-21 (IL-21)
2501/065	• Modulators of histone acetylation	2501/2322	• • • Interleukin-22 (IL-22)
2501/07	• Heat shock proteins	2501/2323	• • • Interleukin-23 (IL-23)
2501/10	• Growth factors	2501/2324	• • • Interleukin-24 (IL-24)
2501/105	• • Insulin-like growth factors [IGF]	2501/2325	• • • Interleukin-25 (IL-25)
2501/11	• • Epidermal growth factor [EGF]	2501/2326	• • • Interleukin-26 (IL-26)
2501/113	• • Acidic fibroblast growth factor (aFGF, FGF-1)	2501/2327	• • • Interleukin-27 (IL-27)
2501/115	• • Basic fibroblast growth factor (bFGF, FGF-2)	2501/2328	• • • Interleukin-28 (IL-28)
2501/117	• • Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)	2501/2329	• • • Interleukin-29 (IL-29)
2501/119	• • Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10	2501/233	• • • Interleukin-30 (IL-30)
2501/12	• • Hepatocyte growth factor [HGF]	2501/2331	• • • Interleukin-31 (IL-31)
2501/125	• • Stem cell factor [SCF], c-kit ligand [KL]	2501/2332	• • • Interleukin-32 (IL-32)
2501/13	• • Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins	2501/2333	• • • Interleukin-33 (IL-33)
2501/135	• • Platelet-derived growth factor [PDGF]	2501/2334	• • • Interleukin-34 (IL-34)
2501/14	• • Erythropoietin [EPO]	2501/2335	• • • Interleukin-35 (IL-35)
2501/145	• • Thrombopoietin [TPO]	2501/235	• • • Leukemia inhibitory factor [LIF]
2501/148	• • Transforming growth factor alpha [TGF- $\alpha$ ]	2501/237	• • Oncostatin M [OSM]
2501/15	• • Transforming growth factor beta (TGF- $\beta$ )	2501/24	• • Interferons [IFN]
2501/155	• • Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor	2501/25	• • Tumour necrosing factors [TNF]
2501/16	• • Activin; Inhibin; Mullerian inhibiting substance	2501/26	• • Flt-3 ligand (CD135L, flk-2 ligand)
2501/165	• • Vascular endothelial growth factor [VEGF]	2501/30	• Hormones ( <a href="#">derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85</a> )
2501/17	• • Angiopoietin	2501/305	• • Growth hormone [GH], aka. somatotropin
2501/175	• • Cardiotrophin	2501/31	• • Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
2501/18	• • Liver cell growth factor (LCGF, Gly-His-Lys)	2501/315	• • Prolactin
2501/185	• • Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)	2501/32	• • Angiotensins [AT], angiotensinogen
2501/19	• • Growth and differentiation factors [GDF]	2501/33	• • Insulin ( <a href="#">together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105</a> )
2501/195	• • Heregulin, neu differentiation factor	2501/335	• • Glucagon; Glucagon-like peptide [GLP]; Exendin
2501/20	• Cytokines; Chemokines	2501/34	• • Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
2501/21	• • Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4	2501/345	• • Gastrin; Cholecystokinins [CCK]
2501/22	• • Colony stimulating factors (G-CSF, GM-CSF)	2501/35	• • Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
2501/23	• • Interleukins [IL]	2501/355	• • Leptin
2501/2301	• • • Interleukin-1 (IL-1)	2501/36	• • Somatostatin
2501/2302	• • • Interleukin-2 (IL-2)	2501/365	• • Endothelin
2501/2303	• • • Interleukin-3 (IL-3)	2501/37	• • Parathyroid hormone [PTH]
2501/2304	• • • Interleukin-4 (IL-4)	2501/375	• • Thyroid stimulating hormone [TSH]
2501/2305	• • • Interleukin-5 (IL-5)	2501/38	• • with nuclear receptors
2501/2306	• • • Interleukin-6 (IL-6)	2501/385	• • • of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
2501/2307	• • • Interleukin-7 (IL-7)	2501/39	• • • Steroid hormones
2501/2308	• • • Interleukin-8 (IL-8)	2501/392	• • • • Sexual steroids
2501/2309	• • • Interleukin-9 (IL-9)	2501/395	• • • Thyroid hormones
2501/231	• • • Interleukin-10 (IL-10)	2501/40	• Regulators of development
2501/2311	• • • Interleukin-11 (IL-11)	2501/405	• • Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
2501/2312	• • • Interleukin-12 (IL-12)	2501/41	• • Hedgehog proteins; Cyclopamine (inhibitor)
2501/2313	• • • Interleukin-13 (IL-13)	2501/415	• • Wnt; Frizzled
		2501/42	• • Notch; Delta; Jagged; Serrate

2501/48	. . Regulators of apoptosis	2502/072	. . adrenal cells
2501/50	. Cell markers; Cell surface determinants	2502/074	. . pinealocytes
2501/505	. . CD4; CD8	2502/076	. . pituitary cells
2501/51	. . B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)	2502/078	. . thyroid, parathyroid cells
2501/515	. . CD3, T-cell receptor complex	2502/08	. cells of the nervous system
2501/52	. . CD40, CD40-ligand (CD154)	2502/081	. . neurons
2501/53	. . CD2	2502/083	. . sensory transducers
2501/58	. . Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)	2502/085	. . eye cells
2501/585	. . Integrins	2502/086	. . glial cells
2501/59	. . Lectins	2502/088	. . neural stem cells
2501/599	. . with CD designations not provided for elsewhere	2502/09	. epidermal cells, skin cells, oral mucosa cells
2501/60	. Transcription factors	2502/091	. . melanocytes
2501/602	. . Sox-2	2502/092	. . hair cells
2501/603	. . Oct-3/4	2502/094	. . keratinocytes
2501/604	. . Klf-4	2502/095	. . mammary cells
2501/605	. . Nanog	2502/097	. . oral mucosa cells
2501/606	. . c-Myc	2502/098	. . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
2501/608	. . Lin28	2502/11	. blood or immune system cells
2501/65	. MicroRNA	2502/1107	. . B cells
2501/70	. Enzymes	2502/1114	. . T cells
2501/71	. . Oxidoreductases (EC 1.)	2502/1121	. . Dendritic cells
2501/72	. . Transferases (EC 2.) ( <a href="#">acetylation of histones C12N 2501/065</a> )	2502/1128	. . Erythrocytes
2501/724	. . . Glycosyltransferases (EC 2.4.)	2502/1135	. . Granulocytes
2501/727	. . . Kinases (EC 2.7.)	2502/1142	. . Osteoclasts
2501/73	. . Hydrolases (EC 3.)	2502/115	. . Platelets, megakaryocytes
2501/734	. . . Proteases (EC 3.4.)	2502/1157	. . Monocytes, macrophages
2501/80	. Neurotransmitters; Neurohormones	2502/1164	. . NK cells
2501/805	. . Acetylcholine	2502/1171	. . Haematopoietic stem cells
2501/81	. . Adrenaline	2502/1178	. . Spleen cells
2501/815	. . Dopamine	2502/1185	. . Thymus cells
2501/82	. . Histamine	2502/1192	. . Lymphatic cells
2501/825	. . Serotonine (5-HT); Melatonin	2502/13	. connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
2501/83	. . Tachykinins, e.g. substance P	2502/1305	. . Adipocytes
2501/835	. . Neuropeptide Y [NPY]; Peptide YY [PYY]	2502/1311	. . Osteocytes, osteoblasts, odontoblasts
2501/84	. . Excitatory amino acids	2502/1317	. . Chondrocytes
2501/845	. . Gamma amino butyric acid [GABA]	2502/1323	. . Adult fibroblasts
2501/85	. Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin	2502/1329	. . Cardiomyocytes
2501/855	. . Corticotropin [ACTH]	2502/1335	. . Skeletal muscle cells, myocytes, myoblasts, myotubes
2501/86	. . Melanocyte-stimulating hormone [MSH]	2502/1341	. . Tenocytes, cells from tendons and ligaments
2501/90	. Polysaccharides	2502/1347	. . Smooth muscle cells
2501/905	. . Hyaluronic acid	2502/1352	. . Mesenchymal stem cells
2501/91	. . Heparin	2502/1358	. . . Bone marrow mesenchymal stem cells (BM-MS)
2501/998	. Proteins not provided for elsewhere	2502/1364	. . . Dental pulp stem cells, dental follicle stem cells
<b>NOTE</b>		2502/137	. . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood
Classification by pathway does not apply.		2502/1376	. . . Mesenchymal stem cells from hair follicles
2501/999	. Small molecules not provided for elsewhere	2502/1382	. . . Adipose-derived stem cells [ADSC], adipose stromal stem cells
<b>NOTE</b>		2502/1388	. . . Mesenchymal stem cells from other natural sources
Classification by pathway does not apply.		2502/1394	. . Bone marrow stromal cells; whole marrow
<b>2502/00</b>	<b>Coculture with; Conditioned medium produced by</b>	2502/14	. hepatocytes
2502/02	. embryonic cells	2502/22	. pancreatic cells
2502/025	. . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly	2502/23	. Gastro-intestinal tract cells
2502/03	. non-embryonic pluripotent stem cells	2502/24	. Genital tract cells, non-germinal cells from gonads
2502/04	. germ cells	2502/243	. . Cells of the female genital tract, non-germinal ovarian cells
2502/07	. endocrine cells		

- 2502/246 . . Cells of the male genital tract, non-germinal testis cells
- 2502/25 . Urinary tract cells, renal cells
- 2502/253 . . Bladder cells
- 2502/256 . . Renal cells
- 2502/27 . Lung cells, respiratory tract cells
- 2502/28 . Vascular endothelial cells
- 2502/30 . tumour cells
- 2502/45 . Artificially induced pluripotent stem cells
- 2502/50 . invertebrate cells
- 2502/70 . Non-animal cells
- 2502/99 . genetically modified cells

**NOTE**

Use [C12N 2501/00](#) to index the expressed products.

**2503/00 Use of cells in diagnostics**

- 2503/02 . Drug screening
- 2503/04 . Screening or testing on artificial tissues
- 2503/06 . . Screening or testing on artificial skin

**2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells****NOTE**

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

- 2506/02 . from embryonic cells
- 2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta
- 2506/03 . from non-embryonic pluripotent stem cells
- 2506/04 . from germ cells
- 2506/07 . from endocrine cells
- 2506/072 . . from adrenal cells
- 2506/074 . . from pinealocytes
- 2506/076 . . from pituitary cells
- 2506/078 . . from thyroid, parathyroid cells
- 2506/08 . from cells of the nervous system
- 2506/09 . from epidermal cells, from skin cells, from oral mucosa cells
- 2506/091 . . from melanocytes
- 2506/092 . . from hair cells
- 2506/094 . . from keratinocytes
- 2506/095 . . from mammary cells
- 2506/097 . . from oral mucosa cells
- 2506/098 . . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- 2506/11 . from blood or immune system cells
- 2506/115 . . from monocytes, from macrophages
- 2506/13 . from connective tissue cells, from mesenchymal cells
- 2506/1307 . . from adult fibroblasts
- 2506/1315 . . from cardiomyocytes
- 2506/1323 . . from skeletal muscle cells
- 2506/133 . . from tenocytes
- 2506/1338 . . from smooth muscle cells
- 2506/1346 . . from mesenchymal stem cells

- 2506/1353 . . . from bone marrow mesenchymal stem cells (BM-MSD)
- 2506/1361 . . . from dental pulp or dental follicle stem cells
- 2506/1369 . . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
- 2506/1376 . . . from mesenchymal stem cells derived from hair follicles
- 2506/1384 . . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- 2506/1392 . . . from mesenchymal stem cells from other natural sources
- 2506/14 . from hepatocytes
- 2506/22 . from pancreatic cells
- 2506/23 . from cells of the gastro-intestinal tract
- 2506/24 . from cells of the genital tract, from non-germinal gonad cells
- 2506/243 . . from cells of the female genital tract cells, from non-germinal ovarian cells
- 2506/246 . . from cells of the male genital tract cells, from non-germinal testis cells
- 2506/25 . from renal cells, from cells of the urinary tract
- 2506/27 . from lung cells, from cells of the respiratory tract
- 2506/28 . from vascular endothelial cells
- 2506/30 . from cancer cells, e.g. reversion of tumour cells

**NOTE**

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- 2506/45 . from artificially induced pluripotent stem cells
- 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes**
- 2509/10 . Mechanical dissociation
- 2510/00 Genetically modified cells**
- 2510/02 . Cells for production
- 2510/04 . Immortalised cells
- 2511/00 Cells for large scale production**
- 2513/00 3D culture**
- 2517/00 Cells related to new breeds of animals**
- 2517/02 . Cells from transgenic animals
- 2517/04 . Cells produced using nuclear transfer
- 2517/10 . Conditioning of cells for *in vitro* fecondation or nuclear transfer
- 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . Sound, e.g. ultrasounds
- 2523/00 Culture process characterised by temperature**
- 2525/00 Culture process characterised by gravity, e.g. microgravity**
- 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00 Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . Stimulation by light
- 2531/00 Microcarriers**

<b>2533/00</b>	<b>Supports or coatings for cell culture, characterised by material</b>	2710/00043	. . . viral genome or elements thereof as genetic vector
2533/10	. Mineral substrates	2710/00044	. . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2533/12	. . Glass	2710/00045	. . . Special targeting system for viral vectors
2533/14	. . Ceramic	2710/00051	. . Methods of production or purification of viral material
2533/18	. . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells	2710/00052	. . . relating to complementing cells and packaging systems for producing virus or viral particles
2533/20	. Small organic molecules	2710/00061	. . Methods of inactivation or attenuation
2533/30	. Synthetic polymers ( <a href="#">thermoreactive polymers</a> , e.g. <a href="#">PNIPAm</a> , <a href="#">C12N 2539/10</a> )	2710/00062	. . . by genetic engineering
2533/32	. . Polylysine, polyornithine	2710/00063	. . . by chemical treatment
2533/40	. . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers	2710/00064	. . . by serial passage
2533/50	. Proteins	2710/00071	. . Demonstrated <u>in vivo</u> effect
2533/52	. . Fibronectin; Laminin	2710/00088	. . For redistribution
2533/54	. . Collagen; Gelatin	2710/10011	. . Adenoviridae
2533/56	. . Fibrin; Thrombin	2710/10021	. . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2533/70	. Polysaccharides	2710/10022	. . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2533/72	. . Chitin, chitosan	2710/10023	. . . Virus like particles [VLP]
2533/74	. . Alginate	2710/10031	. . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2533/76	. . Agarose, agar-agar	2710/10032	. . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2533/78	. . Cellulose	2710/10033	. . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2533/80	. . Hyaluronan	2710/10034	. . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2533/90	. Substrates of biological origin, e.g. extracellular matrix, decellularised tissue	2710/10041	. . . Use of virus, viral particle or viral elements as a vector
2533/92	. . Amnion; Decellularised dermis or mucosa	2710/10042	. . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
<b>2535/00</b>	<b>Supports or coatings for cell culture characterised by topography</b>	2710/10043	. . . . viral genome or elements thereof as genetic vector
2535/10	. Patterned coating	2710/10044	. . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
<b>2537/00</b>	<b>Supports and/or coatings for cell culture characterised by physical or chemical treatment</b>	2710/10045	. . . . Special targeting system for viral vectors
2537/10	. Cross-linking	2710/10051	. . . Methods of production or purification of viral material
<b>2539/00</b>	<b>Supports and/or coatings for cell culture characterised by properties</b>	2710/10052	. . . . relating to complementing cells and packaging systems for producing virus or viral particles
2539/10	. Coating allowing for selective detachment of cells, e.g. thermoreactive coating	2710/10061	. . . Methods of inactivation or attenuation
<b>2700/00</b>	<b>Viruses</b>	2710/10062	. . . . by genetic engineering
<b>2710/00</b>	<b>dsDNA Viruses (<a href="#">not used</a>)</b>	2710/10063	. . . . by chemical treatment
2710/00011	. dsDNA Viruses	2710/10064	. . . . by serial passage
2710/00021	. . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10071	. . . Demonstrated <u>in vivo</u> effect
2710/00022	. . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10088	. . . For redistribution
2710/00023	. . Virus like particles [VLP]	2710/10111	. . . Atadenovirus, e.g. ovine adenovirus D
2710/00031	. . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10121	. . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/00032	. . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10122	. . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/00033	. . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10123	. . . . Virus like particles [VLP]
2710/00034	. . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10131	. . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/00041	. . Use of virus, viral particle or viral elements as a vector		
2710/00042	. . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule		

2710/10132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10264	. . . . .	by serial passage
2710/10133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10271	. . . .	Demonstrated <u>in vivo</u> effect
2710/10134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10288	. . . .	For redistribution
2710/10141	. . . .	Use of virus, viral particle or viral elements as a vector	2710/10311	. . .	Mastadenovirus, e.g. human or simian adenoviruses
2710/10142	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/10321	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10143	. . . . .	viral genome or elements thereof as genetic vector	2710/10322	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10144	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/10323	. . . .	Virus like particles [VLP]
2710/10145	. . . . .	Special targeting system for viral vectors	2710/10331	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10151	. . . .	Methods of production or purification of viral material	2710/10332	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10152	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/10333	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10161	. . . .	Methods of inactivation or attenuation	2710/10334	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10162	. . . . .	by genetic engineering	2710/10341	. . . .	Use of virus, viral particle or viral elements as a vector
2710/10163	. . . . .	by chemical treatment	2710/10342	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/10164	. . . . .	by serial passage	2710/10343	. . . . .	viral genome or elements thereof as genetic vector
2710/10171	. . . .	Demonstrated <u>in vivo</u> effect	2710/10344	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/10188	. . . .	For redistribution	2710/10345	. . . . .	Special targeting system for viral vectors
2710/10211	. . .	Aviadenovirus, e.g. fowl adenovirus A	2710/10351	. . . .	Methods of production or purification of viral material
2710/10221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/10352	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/10222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/10361	. . . .	Methods of inactivation or attenuation
2710/10223	. . . .	Virus like particles [VLP]	2710/10362	. . . . .	by genetic engineering
2710/10231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/10363	. . . . .	by chemical treatment
2710/10232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/10364	. . . . .	by serial passage
2710/10233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/10371	. . . .	Demonstrated <u>in vivo</u> effect
2710/10234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/10388	. . . .	For redistribution
2710/10241	. . . .	Use of virus, viral particle or viral elements as a vector	2710/12011	. .	Asfarviridae
2710/10242	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/10243	. . . . .	viral genome or elements thereof as genetic vector	2710/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/10244	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/12023	. . .	Virus like particles [VLP]
2710/10245	. . . . .	Special targeting system for viral vectors	2710/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/10251	. . . .	Methods of production or purification of viral material	2710/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/10252	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/10261	. . . .	Methods of inactivation or attenuation	2710/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/10262	. . . . .	by genetic engineering	2710/12041	. . .	Use of virus, viral particle or viral elements as a vector
2710/10263	. . . . .	by chemical treatment	2710/12042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule



2710/12043	. . . .	viral genome or elements thereof as genetic vector	2710/14131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/12044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/14132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/12045	. . . .	Special targeting system for viral vectors	2710/14133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/12051	. . . .	Methods of production or purification of viral material	2710/14134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/12052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/14141	. . . .	Use of virus, viral particle or viral elements as a vector
2710/12061	. . . .	Methods of inactivation or attenuation	2710/14142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/12062	. . . .	by genetic engineering	2710/14143	. . . .	viral genome or elements thereof as genetic vector
2710/12063	. . . .	by chemical treatment	2710/14144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/12064	. . . .	by serial passage	2710/14145	. . . .	Special targeting system for viral vectors
2710/12071	. . . .	Demonstrated <u>in vivo</u> effect	2710/14151	. . . .	Methods of production or purification of viral material
2710/12088	. . . .	For redistribution	2710/14152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/14011	. . . .	Baculoviridae	2710/14161	. . . .	Methods of inactivation or attenuation
2710/14021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/14162	. . . .	by genetic engineering
2710/14022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/14163	. . . .	by chemical treatment
2710/14023	. . . .	Virus like particles [VLP]	2710/14164	. . . .	by serial passage
2710/14031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/14171	. . . .	Demonstrated <u>in vivo</u> effect
2710/14032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/14188	. . . .	For redistribution
2710/14033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16011	. . . .	Herpesviridae
2710/14034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/14041	. . . .	Use of virus, viral particle or viral elements as a vector	2710/16022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/14042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16023	. . . .	Virus like particles [VLP]
2710/14043	. . . .	viral genome or elements thereof as genetic vectore	2710/16031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/14044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/14045	. . . .	Special targeting system for viral vectors	2710/16033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/14051	. . . .	Methods of production or purification of viral material	2710/16034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/14052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16041	. . . .	Use of virus, viral particle or viral elements as a vector
2710/14061	. . . .	Methods of inactivation or attenuation	2710/16042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/14062	. . . .	by genetic engineering	2710/16043	. . . .	viral genome or elements thereof as genetic vector
2710/14063	. . . .	by chemical treatment	2710/16044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/14064	. . . .	by serial passage	2710/16045	. . . .	Special targeting system for viral vectors
2710/14071	. . . .	Demonstrated <u>in vivo</u> effect	2710/16051	. . . .	Methods of production or purification of viral material
2710/14088	. . . .	For redistribution	2710/16052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/14111	. . . .	Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus	2710/16061	. . . .	Methods of inactivation or attenuation
2710/14121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2710/14122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2710/14123	. . . .	Virus like particles [VLP]			

- 2710/16062 . . . . by genetic engineering
- 2710/16063 . . . . by chemical treatment
- 2710/16064 . . . . by serial passage
- 2710/16071 . . . Demonstrated in vivo effect
- 2710/16088 . . . For redistribution
- 2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5
- 2710/16121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 . . . . Virus like particles [VLP]
- 2710/16131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 . . . . . viral genome or elements thereof as genetic vector
- 2710/16144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 . . . . . Special targeting system for viral vectors
- 2710/16151 . . . . Methods of production or purification of viral material
- 2710/16152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 . . . . Methods of inactivation or attenuation
- 2710/16162 . . . . . by genetic engineering
- 2710/16163 . . . . . by chemical treatment
- 2710/16164 . . . . . by serial passage
- 2710/16171 . . . . Demonstrated in vivo effect
- 2710/16188 . . . . For redistribution
- 2710/16211 . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 . . . . Virus like particles [VLP]
- 2710/16231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16241 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16243 . . . . . viral genome or elements thereof as genetic vector
- 2710/16244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16245 . . . . . Special targeting system for viral vectors
- 2710/16251 . . . . Methods of production or purification of viral material
- 2710/16252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16261 . . . . Methods of inactivation or attenuation
- 2710/16262 . . . . . by genetic engineering
- 2710/16263 . . . . . by chemical treatment
- 2710/16264 . . . . . by serial passage
- 2710/16271 . . . . Demonstrated in vivo effect
- 2710/16288 . . . . For redistribution
- 2710/16311 . . . . Marek's disease virus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- 2710/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 . . . . Virus like particles [VLP]
- 2710/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 . . . . Use of virus, viral particle or viral elements as a vector
- 2710/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 . . . . . viral genome or elements thereof as genetic vector
- 2710/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 . . . . . Special targeting system for viral vectors
- 2710/16351 . . . . Methods of production or purification of viral material
- 2710/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16361 . . . . Methods of inactivation or attenuation
- 2710/16362 . . . . . by genetic engineering
- 2710/16363 . . . . . by chemical treatment
- 2710/16364 . . . . . by serial passage
- 2710/16371 . . . . Demonstrated in vivo effect
- 2710/16388 . . . . For redistribution
- 2710/16411 . . . . Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

2710/16423	. . . .	Virus like particles [VLP]	2710/16561	. . . .	Methods of inactivation or attenuation
2710/16431	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16562	. . . . .	by genetic engineering
2710/16432	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16563	. . . . .	by chemical treatment
2710/16433	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16564	. . . . .	by serial passage
2710/16434	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/16571	. . . .	Demonstrated <u>in vivo</u> effect
2710/16441	. . . .	Use of virus, viral particle or viral elements as a vector	2710/16588	. . . .	For redistribution
2710/16442	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16611	. . . .	Simplexvirus, e.g. human herpesvirus 1, 2
2710/16443	. . . . .	viral genome or elements thereof as genetic vector	2710/16621	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16444	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16622	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16445	. . . . .	Special targeting system for viral vectors	2710/16623	. . . .	Virus like particles [VLP]
2710/16451	. . . .	Methods of production or purification of viral material	2710/16631	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16452	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16632	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16461	. . . .	Methods of inactivation or attenuation	2710/16633	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16462	. . . . .	by genetic engineering	2710/16634	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16463	. . . . .	by chemical treatment	2710/16641	. . . .	Use of virus, viral particle or viral elements as a vector
2710/16464	. . . . .	by serial passage	2710/16642	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16471	. . . .	Demonstrated <u>in vivo</u> effect	2710/16643	. . . . .	viral genome or elements thereof as genetic vector
2710/16488	. . . .	For redistribution	2710/16644	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16511	. . . .	Roseolovirus, e.g. human herpesvirus 6, 7	2710/16645	. . . . .	Special targeting system for viral vectors
2710/16521	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/16651	. . . .	Methods of production or purification of viral material
2710/16522	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/16652	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16523	. . . .	Virus like particles [VLP]	2710/16661	. . . .	Methods of inactivation or attenuation
2710/16531	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/16662	. . . . .	by genetic engineering
2710/16532	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/16663	. . . . .	by chemical treatment
2710/16533	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/16664	. . . . .	by serial passage
2710/16534	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral	2710/16671	. . . .	Demonstrated <u>in vivo</u> effect
2710/16541	. . . .	Use of virus, viral particle or viral elements as a vector	2710/16688	. . . .	For redistribution
2710/16542	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/16711	. . . .	Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
2710/16543	. . . . .	viral genome or elements thereof as genetic vector	2710/16721	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/16544	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/16722	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/16545	. . . . .	Special targeting system for viral vectors	2710/16723	. . . .	Virus like particles [VLP]
2710/16551	. . . .	Methods of production or purification of viral material	2710/16731	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16552	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/16732	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
			2710/16733	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2710/16734	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
			2710/16741	. . . .	Use of virus, viral particle or viral elements as a vector

2710/16742	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/16743	. . . .	viral genome or elements thereof as genetic vector	2710/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/16744	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/20033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/16745	. . . .	Special targeting system for viral vectors	2710/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/16751	. . . .	Methods of production or purification of viral material	2710/20041	. . .	Use of virus, viral particle or viral elements as a vector
2710/16752	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/20042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/16761	. . . .	Methods of inactivation or attenuation	2710/20043	. . . .	viral genome or elements thereof as genetic vector
2710/16762	. . . .	by genetic engineering	2710/20044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/16763	. . . .	by chemical treatment	2710/20045	. . . .	Special targeting system for viral vectors
2710/16764	. . . .	by serial passage	2710/20051	. . .	Methods of production or purification of viral material
2710/16771	. . . .	Demonstrated <u>in vivo</u> effect	2710/20052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/16788	. . . .	For redistribution	2710/20061	. . .	Methods of inactivation or attenuation
2710/18011	. .	Nimaviridae	2710/20062	. . . .	by genetic engineering
2710/18021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/20063	. . . .	by chemical treatment
2710/18022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/20064	. . . .	by serial passage
2710/18023	. . .	Virus like particles [VLP]	2710/20071	. . .	Demonstrated <u>in vivo</u> effect
2710/18031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/20088	. . .	For redistribution
2710/18032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/22011	. .	Polyomaviridae, e.g. polyoma, SV40, JC
2710/18033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/22021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/18034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/22022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/18041	. . .	Use of virus, viral particle or viral elements as a vector	2710/22023	. . .	Virus like particles [VLP]
2710/18042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/22031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/18043	. . . .	viral genome or elements thereof as genetic vector	2710/22032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/18044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/22033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/18045	. . . .	Special targeting system for viral vectors	2710/22034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/18051	. . .	Methods of production or purification of viral material	2710/22041	. . .	Use of virus, viral particle or viral elements as a vector
2710/18052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/22042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/18061	. . .	Methods of inactivation or attenuation	2710/22043	. . . .	viral genome or elements thereof as genetic vector
2710/18062	. . . .	by genetic engineering	2710/22044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/18063	. . . .	by chemical treatment	2710/22045	. . . .	Special targeting system for viral vectors
2710/18064	. . . .	by serial passage	2710/22051	. . .	Methods of production or purification of viral material
2710/18071	. . .	Demonstrated <u>in vivo</u> effect	2710/22052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/18088	. . .	For redistribution	2710/22061	. . .	Methods of inactivation or attenuation
2710/20011	. .	Papillomaviridae			
2710/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2710/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2710/20023	. . .	Virus like particles [VLP]			

2710/22062	. . . .	by genetic engineering	2710/24143	. . . .	viral genome or elements thereof as genetic vector
2710/22063	. . . .	by chemical treatment	2710/24144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/22064	. . . .	by serial passage	2710/24145	. . . .	Special targeting system for viral vectors
2710/22071	. . .	Demonstrated <u>in vivo</u> effect	2710/24151	. . . .	Methods of production or purification of viral material
2710/22088	. . .	For redistribution	2710/24152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/24011	. .	Poxviridae	2710/24161	. . . .	Methods of inactivation or attenuation
2710/24021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/24162	. . . .	by genetic engineering
2710/24022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/24163	. . . .	by chemical treatment
2710/24023	. . .	Virus like particles [VLP]	2710/24164	. . . .	by serial passage
2710/24031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/24171	. . . .	Demonstrated <u>in vivo</u> effect
2710/24032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/24188	. . . .	For redistribution
2710/24033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2710/24211	. . .	Parapoxvirus, e.g. Orf virus
2710/24034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2710/24221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24041	. . .	Use of virus, viral particle or viral elements as a vector	2710/24222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2710/24042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2710/24223	. . . .	Virus like particles [VLP]
2710/24043	. . . .	viral genome or elements thereof as genetic vector	2710/24231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2710/24044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2710/24232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2710/24045	. . . .	Special targeting system for viral vectors	2710/24233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2710/24051	. . .	Methods of production or purification of viral material	2710/24234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2710/24052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2710/24241	. . . .	Use of virus, viral particle or viral elements as a vector
2710/24061	. . .	Methods of inactivation or attenuation	2710/24242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2710/24062	. . . .	by genetic engineering	2710/24243	. . . .	viral genome or elements thereof as genetic vector
2710/24063	. . . .	by chemical treatment	2710/24244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2710/24064	. . . .	by serial passage	2710/24245	. . . .	Special targeting system for viral vectors
2710/24071	. . .	Demonstrated <u>in vivo</u> effect	2710/24251	. . . .	Methods of production or purification of viral material
2710/24088	. . .	For redistribution	2710/24252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2710/24111	. . .	Orthopoxvirus, e.g. vaccinia virus, variola	2710/24261	. . . .	Methods of inactivation or attenuation
2710/24121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2710/24262	. . . .	by genetic engineering
2710/24122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2710/24263	. . . .	by chemical treatment
2710/24123	. . . .	Virus like particles [VLP]	2710/24264	. . . .	by serial passage
2710/24131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2710/24271	. . . .	Demonstrated <u>in vivo</u> effect
2710/24132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2710/24288	. . . .	For redistribution
2710/24133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	<b>2720/00</b>	<b>dsRNA Viruses (not used)</b>	
2710/24134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2720/00011	. .	dsRNA Viruses
2710/24141	. . . .	Use of virus, viral particle or viral elements as a vector	2720/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2710/24142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2720/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2720/00023	. .	Virus like particles [VLP]



- 2720/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . . Special targeting system for viral vectors
- 2720/00051 . . . Methods of production or purification of viral material
- 2720/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . . Methods of inactivation or attenuation
- 2720/00062 . . . . by genetic engineering
- 2720/00063 . . . . by chemical treatment
- 2720/00064 . . . . by serial passage
- 2720/00071 . . . Demonstrated in vivo effect
- 2720/00088 . . . For redistribution
- 2720/10011 . . . Birnaviridae
- 2720/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . . Virus like particles [VLP]
- 2720/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2720/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 . . . . . viral genome or elements thereof as genetic vector
- 2720/10044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 . . . . . Special targeting system for viral vectors
- 2720/10051 . . . . Methods of production or purification of viral material
- 2720/10052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 . . . . Methods of inactivation or attenuation
- 2720/10062 . . . . . by genetic engineering
- 2720/10063 . . . . . by chemical treatment
- 2720/10064 . . . . . by serial passage
- 2720/10071 . . . . Demonstrated in vivo effect
- 2720/10088 . . . . For redistribution
- 2720/12011 . . . . Reoviridae
- 2720/12021 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 . . . . . Virus like particles [VLP]
- 2720/12031 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12034 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 . . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12042 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 . . . . . . viral genome or elements thereof as genetic vector
- 2720/12044 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 . . . . . . Special targeting system for viral vectors
- 2720/12051 . . . . . Methods of production or purification of viral material
- 2720/12052 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 . . . . . Methods of inactivation or attenuation
- 2720/12062 . . . . . . by genetic engineering
- 2720/12063 . . . . . . by chemical treatment
- 2720/12064 . . . . . . by serial passage
- 2720/12071 . . . . . Demonstrated in vivo effect
- 2720/12088 . . . . . For redistribution
- 2720/12111 . . . . . Orbivirus, e.g. bluetongue virus
- 2720/12121 . . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 . . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 . . . . . . Virus like particles [VLP]
- 2720/12131 . . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 . . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 . . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 . . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 . . . . . . Use of virus, viral particle or viral elements as a vector
- 2720/12142 . . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2720/12143	. . . .	viral genome or elements thereof as genetic vector	2720/12332	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2720/12333	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12145	. . . .	Special targeting system for viral vectors	2720/12334	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12151	. . . .	Methods of production or purification of viral material	2720/12341	. . . .	Use of virus, viral particle or viral elements as a vector
2720/12152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2720/12342	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12161	. . . .	Methods of inactivation or attenuation	2720/12343	. . . .	viral genome or elements thereof as genetic vector
2720/12162	. . . .	by genetic engineering	2720/12344	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12163	. . . .	by chemical treatment	2720/12345	. . . .	Special targeting system for viral vectors
2720/12164	. . . .	by serial passage	2720/12351	. . . .	Methods of production or purification of viral material
2720/12171	. . . .	Demonstrated <u>in vivo</u> effect	2720/12352	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12188	. . . .	For redistribution	2720/12361	. . . .	Methods of inactivation or attenuation
2720/12211	. . . .	Orthoreovirus, e.g. mammalian orthoreovirus	2720/12362	. . . .	by genetic engineering
2720/12221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2720/12363	. . . .	by chemical treatment
2720/12222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2720/12364	. . . .	by serial passage
2720/12223	. . . .	Virus like particles [VLP]	2720/12371	. . . .	Demonstrated <u>in vivo</u> effect
2720/12231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2720/12388	. . . .	For redistribution
2720/12232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	<b>2730/00</b>		<b>Reverse Transcribing DNA Viruses (not used)</b>
2720/12233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2730/00011	. . . .	Reverse Transcribing DNA Viruses
2720/12234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2730/00021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2720/12241	. . . .	Use of virus, viral particle or viral elements as a vector	2730/00022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2720/12242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2730/00023	. . . .	Virus like particles [VLP]
2720/12243	. . . .	viral genome or elements thereof as genetic vector	2730/00031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2720/12244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2730/00032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2720/12245	. . . .	Special targeting system for viral vectors	2730/00033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2720/12251	. . . .	Methods of production or purification of viral material	2730/00034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2720/12252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2730/00041	. . . .	Use of virus, viral particle or viral elements as a vector
2720/12261	. . . .	Methods of inactivation or attenuation	2730/00042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2720/12262	. . . .	by genetic engineering	2730/00043	. . . .	viral genome or elements thereof as genetic vector
2720/12263	. . . .	by chemical treatment	2730/00044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2720/12264	. . . .	by serial passage	2730/00045	. . . .	Special targeting system for viral vectors
2720/12271	. . . .	Demonstrated <u>in vivo</u> effect	2730/00051	. . . .	Methods of production or purification of viral material
2720/12288	. . . .	For redistribution	2730/00052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2720/12311	. . . .	Rotavirus, e.g. rotavirus A	2730/00061	. . . .	Methods of inactivation or attenuation
2720/12321	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/00062	. . . .	by genetic engineering
2720/12322	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2720/12323	. . . .	Virus like particles [VLP]			
2720/12331	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

2730/00063	. . .	by chemical treatment	2730/10143	. . . . .	viral genome or elements thereof as genetic vector
2730/00064	. . .	by serial passage	2730/10144	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/00071	. .	Demonstrated <u>in vivo</u> effect	2730/10145	. . . . .	Special targeting system for viral vectors
2730/00088	. .	For redistribution	2730/10151	. . . . .	Methods of production or purification of viral material
2730/10011	. .	Hepadnaviridae	2730/10152	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2730/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2730/10161	. . . . .	Methods of inactivation or attenuation
2730/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2730/10162	. . . . .	by genetic engineering
2730/10023	. . .	Virus like particles [VLP]	2730/10163	. . . . .	by chemical treatment
2730/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2730/10164	. . . . .	by serial passage
2730/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2730/10171	. . . . .	Demonstrated <u>in vivo</u> effect
2730/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2730/10188	. . . . .	For redistribution
2730/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	<b>2740/00</b>		<b>Reverse Transcribing RNA Viruses (not used)</b>
2730/10041	. . .	Use of virus, viral particle or viral elements as a vector	2740/00011	. .	Reverse Transcribing RNA Viruses
2730/10042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2730/10043	. . . . .	viral genome or elements thereof as genetic vector	2740/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2730/10044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/00023	. .	Virus like particles [VLP]
2730/10045	. . . . .	Special targeting system for viral vectors	2740/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2730/10051	. . .	Methods of production or purification of viral material	2740/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2730/10052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2730/10061	. . .	Methods of inactivation or attenuation	2740/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2730/10062	. . . . .	by genetic engineering	2740/00041	. .	Use of virus, viral particle or viral elements as a vector
2730/10063	. . . . .	by chemical treatment	2740/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2730/10064	. . . . .	by serial passage	2740/00043	. . .	viral genome or elements thereof as genetic vector
2730/10071	. . .	Demonstrated <u>in vivo</u> effect	2740/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2730/10088	. . .	For redistribution	2740/00045	. . .	Special targeting system for viral vectors
2730/10111	. . .	Orthohepadnavirus, e.g. hepatitis B virus	2740/00051	. .	Methods of production or purification of viral material
2730/10121	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles
2730/10122	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/00061	. .	Methods of inactivation or attenuation
2730/10123	. . . . .	Virus like particles [VLP]	2740/00062	. . .	by genetic engineering
2730/10131	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/00063	. . .	by chemical treatment
2730/10132	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/00064	. . .	by serial passage
2730/10133	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/00071	. .	Demonstrated <u>in vivo</u> effect
2730/10134	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/00088	. .	For redistribution
2730/10141	. . . . .	Use of virus, viral particle or viral elements as a vector	2740/10011	. .	Retroviridae
2730/10142	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2740/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2740/10023	. . .	Virus like particles [VLP]

2740/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/11062	. . . . .	by genetic engineering
2740/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/11063	. . . . .	by chemical treatment
2740/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/11064	. . . . .	by serial passage
2740/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/11071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/10041	. . .	Use of virus, viral particle or viral elements as a vector	2740/11088	. . . . .	For redistribution
2740/10042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/12011	. . .	Betaretrovirus, e.g. mouse mammary tumour virus
2740/10043	. . . . .	viral genome or elements thereof as genetic vector	2740/12021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/10044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/12022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/10045	. . . . .	Special targeting system for viral vectors	2740/12023	. . . . .	Virus like particles [VLP]
2740/10051	. . .	Methods of production or purification of viral material	2740/12031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/10052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/12032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/10061	. . .	Methods of inactivation or attenuation	2740/12033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/10062	. . . . .	by genetic engineering	2740/12034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/10063	. . . . .	by chemical treatment	2740/12041	. . . . .	Use of virus, viral particle or viral elements as a vector
2740/10064	. . . . .	by serial passage	2740/12042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/10071	. . .	Demonstrated <u>in vivo</u> effect	2740/12043	. . . . .	viral genome or elements thereof as genetic vector
2740/10088	. . .	For redistribution	2740/12044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/11011	. . .	Alpharetrovirus, e.g. avian leucosis virus	2740/12045	. . . . .	Special targeting system for viral vectors
2740/11021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/12051	. . . . .	Methods of production or purification of viral material
2740/11022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/12052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/11023	. . . . .	Virus like particles [VLP]	2740/12061	. . . . .	Methods of inactivation or attenuation
2740/11031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/12062	. . . . .	by genetic engineering
2740/11032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/12063	. . . . .	by chemical treatment
2740/11033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/12064	. . . . .	by serial passage
2740/11034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/12071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/11041	. . . . .	Use of virus, viral particle or viral elements as a vector	2740/12088	. . . . .	For redistribution
2740/11042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/13011	. . .	Gammaretrovirus, e.g. murine leukaemia virus
2740/11043	. . . . .	viral genome or elements thereof as genetic vector	2740/13021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/11044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/13022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/11045	. . . . .	Special targeting system for viral vectors	2740/13023	. . . . .	Virus like particles [VLP]
2740/11051	. . . . .	Methods of production or purification of viral material	2740/13031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/11052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/13032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/11061	. . . . .	Methods of inactivation or attenuation	2740/13033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2740/13034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
			2740/13041	. . . . .	Use of virus, viral particle or viral elements as a vector

2740/13042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/15031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/13043	. . . .	viral genome or elements thereof as genetic vector	2740/15032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/13044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/15033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/13045	. . . .	Special targeting system for viral vectors	2740/15034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/13051	. . . .	Methods of production or purification of viral material	2740/15041	. . . .	Use of virus, viral particle or viral elements as a vector
2740/13052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/15042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/13061	. . . .	Methods of inactivation or attenuation	2740/15043	. . . .	viral genome or elements thereof as genetic vector
2740/13062	. . . .	by genetic engineering	2740/15044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/13063	. . . .	by chemical treatment	2740/15045	. . . .	Special targeting system for viral vectors
2740/13064	. . . .	by serial passage	2740/15051	. . . .	Methods of production or purification of viral material
2740/13071	. . . .	Demonstrated <u>in vivo</u> effect	2740/15052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/13088	. . . .	For redistribution	2740/15061	. . . .	Methods of inactivation or attenuation
2740/14011	. . .	Deltaretrovirus, e.g. bovine leukaemia virus	2740/15062	. . . .	by genetic engineering
2740/14021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2740/15063	. . . .	by chemical treatment
2740/14022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2740/15064	. . . .	by serial passage
2740/14023	. . . .	Virus like particles [VLP]	2740/15071	. . . .	Demonstrated <u>in vivo</u> effect
2740/14031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2740/15088	. . . .	For redistribution
2740/14032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2740/16011	. . .	Human Immunodeficiency Virus, HIV
2740/14033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2740/16021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/14034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2740/16022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/14041	. . . .	Use of virus, viral particle or viral elements as a vector	2740/16023	. . . .	Virus like particles [VLP]
2740/14042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2740/16031	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/14043	. . . .	viral genome or elements thereof as genetic vector	2740/16032	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/14044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2740/16033	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/14045	. . . .	Special targeting system for viral vectors	2740/16034	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/14051	. . . .	Methods of production or purification of viral material	2740/16041	. . . .	Use of virus, viral particle or viral elements as a vector
2740/14052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2740/16042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/14061	. . . .	Methods of inactivation or attenuation	2740/16043	. . . .	viral genome or elements thereof as genetic vector
2740/14062	. . . .	by genetic engineering	2740/16044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/14063	. . . .	by chemical treatment	2740/16045	. . . .	Special targeting system for viral vectors
2740/14064	. . . .	by serial passage	2740/16051	. . . .	Methods of production or purification of viral material
2740/14071	. . . .	Demonstrated <u>in vivo</u> effect	2740/16052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/14088	. . . .	For redistribution	2740/16061	. . . .	Methods of inactivation or attenuation
2740/15011	. . .	Lentivirus, not HIV, e.g. FIV, SIV			
2740/15021	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2740/15022	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2740/15023	. . . .	Virus like particles [VLP]			



2740/16062	. . . . .	by genetic engineering	2740/17061	. . . . .	Methods of inactivation or attenuation
2740/16063	. . . . .	by chemical treatment	2740/17062	. . . . .	by genetic engineering
2740/16064	. . . . .	by serial passage	2740/17063	. . . . .	by chemical treatment
2740/16071	. . . . .	Demonstrated <u>in vivo</u> effect	2740/17064	. . . . .	by serial passage
2740/16088	. . . . .	For redistribution	2740/17071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/16111	. . . . .	concerning HIV env	2740/17088	. . . . .	For redistribution
2740/16122	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	<b>2750/00</b>		<b>ssDNA Viruses (not used)</b>
2740/16134	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2750/00011	. . . . .	ssDNA Viruses
2740/16171	. . . . .	Demonstrated <u>in vivo</u> effect	2750/00021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/16188	. . . . .	For redistribution	2750/00022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/16211	. . . . .	concerning HIV gagpol	2750/00023	. . . . .	Virus like particles [VLP]
2740/16222	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/00031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/16234	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2750/00032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/16271	. . . . .	Demonstrated <u>in vivo</u> effect	2750/00033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2740/16288	. . . . .	For redistribution	2750/00034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2740/16311	. . . . .	concerning HIV regulatory proteins	2750/00041	. . . . .	Use of virus, viral particle or viral elements as a vector
2740/16322	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/00042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2740/16334	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2750/00043	. . . . .	viral genome or elements thereof as genetic vector
2740/16371	. . . . .	Demonstrated <u>in vivo</u> effect	2750/00044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2740/16388	. . . . .	For redistribution	2750/00045	. . . . .	Special targeting system for viral vectors
2740/17011	. . . . .	Spumavirus, e.g. chimpanzee foamy virus	2750/00051	. . . . .	Methods of production or purification of viral material
2740/17021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2750/00052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2740/17022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/00061	. . . . .	Methods of inactivation or attenuation
2740/17023	. . . . .	Virus like particles [VLP]	2750/00062	. . . . .	by genetic engineering
2740/17031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2750/00063	. . . . .	by chemical treatment
2740/17032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2750/00064	. . . . .	by serial passage
2740/17033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2750/00071	. . . . .	Demonstrated <u>in vivo</u> effect
2740/17034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2750/00088	. . . . .	For redistribution
2740/17041	. . . . .	Use of virus, viral particle or viral elements as a vector	2750/10011	. . . . .	Circoviridae
2740/17042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2750/10021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2740/17043	. . . . .	viral genome or elements thereof as genetic vector	2750/10022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2740/17044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2750/10023	. . . . .	Virus like particles [VLP]
2740/17045	. . . . .	Special targeting system for viral vectors	2750/10031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2740/17051	. . . . .	Methods of production or purification of viral material	2750/10032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2740/17052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2750/10033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
			2750/10034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
			2750/10041	. . . . .	Use of virus, viral particle or viral elements as a vector

- 2750/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 . . . . viral genome or elements thereof as genetic vector
- 2750/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 . . . . Special targeting system for viral vectors
- 2750/10051 . . . . Methods of production or purification of viral material
- 2750/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 . . . . Methods of inactivation or attenuation
- 2750/10062 . . . . by genetic engineering
- 2750/10063 . . . . by chemical treatment
- 2750/10064 . . . . by serial passage
- 2750/10071 . . . . Demonstrated in vivo effect
- 2750/10088 . . . . For redistribution
- 2750/12011 . . . . Geminiviridae
- 2750/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . . Virus like particles [VLP]
- 2750/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 . . . . viral genome or elements thereof as genetic vector
- 2750/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 . . . . Special targeting system for viral vectors
- 2750/12051 . . . . Methods of production or purification of viral material
- 2750/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . . Methods of inactivation or attenuation
- 2750/12062 . . . . by genetic engineering
- 2750/12063 . . . . by chemical treatment
- 2750/12064 . . . . by serial passage
- 2750/12071 . . . . Demonstrated in vivo effect
- 2750/12088 . . . . For redistribution
- 2750/14011 . . . . Parvoviridae
- 2750/14021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . . Virus like particles [VLP]
- 2750/14031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 . . . . viral genome or elements thereof as genetic vector
- 2750/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 . . . . Special targeting system for viral vectors
- 2750/14051 . . . . Methods of production or purification of viral material
- 2750/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . . Methods of inactivation or attenuation
- 2750/14062 . . . . by genetic engineering
- 2750/14063 . . . . by chemical treatment
- 2750/14064 . . . . by serial passage
- 2750/14071 . . . . Demonstrated in vivo effect
- 2750/14088 . . . . For redistribution
- 2750/14111 . . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 . . . . Virus like particles [VLP]
- 2750/14131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2750/14142 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 . . . . viral genome or elements thereof as genetic vector
- 2750/14144 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 . . . . Special targeting system for viral vectors
- 2750/14151 . . . . Methods of production or purification of viral material
- 2750/14152 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 . . . . Methods of inactivation or attenuation

2750/14162	. . . . .	by genetic engineering	2750/14343	. . . . .	viral genome or elements thereof as genetic vector
2750/14163	. . . . .	by chemical treatment	2750/14344	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14164	. . . . .	by serial passage	2750/14345	. . . . .	Special targeting system for viral vectors
2750/14171	. . . . .	Demonstrated <u>in vivo</u> effect	2750/14351	. . . . .	Methods of production or purification of viral material
2750/14188	. . . . .	For redistribution	2750/14352	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2750/14211	. . . . .	Erythrovirus, e.g. B19 virus	2750/14361	. . . . .	Methods of inactivation or attenuation
2750/14221	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2750/14362	. . . . .	by genetic engineering
2750/14222	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2750/14363	. . . . .	by chemical treatment
2750/14223	. . . . .	Virus like particles [VLP]	2750/14364	. . . . .	by serial passage
2750/14231	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2750/14371	. . . . .	Demonstrated <u>in vivo</u> effect
2750/14232	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2750/14388	. . . . .	For redistribution
2750/14233	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	<b>2760/00</b>		<b>ssRNA Viruses negative-sense (not used)</b>
2750/14234	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/00011	. . . . .	ssRNA Viruses negative-sense
2750/14241	. . . . .	Use of virus, viral particle or viral elements as a vector	2760/00021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14242	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/00022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2750/14243	. . . . .	viral genome or elements thereof as genetic vector	2760/00023	. . . . .	Virus like particles [VLP]
2750/14244	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/00031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2750/14245	. . . . .	Special targeting system for viral vectors	2760/00032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2750/14251	. . . . .	Methods of production or purification of viral material	2760/00033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2750/14252	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/00034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2750/14261	. . . . .	Methods of inactivation or attenuation	2760/00041	. . . . .	Use of virus, viral particle or viral elements as a vector
2750/14262	. . . . .	by genetic engineering	2760/00042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2750/14263	. . . . .	by chemical treatment	2760/00043	. . . . .	viral genome or elements thereof as genetic vector
2750/14264	. . . . .	by serial passage	2760/00044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2750/14271	. . . . .	Demonstrated <u>in vivo</u> effect	2760/00045	. . . . .	Special targeting system for viral vectors
2750/14288	. . . . .	For redistribution	2760/00051	. . . . .	Methods of production or purification of viral material
2750/14311	. . . . .	Parvovirus, e.g. minute virus of mice	2760/00052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2750/14321	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/00061	. . . . .	Methods of inactivation or attenuation
2750/14322	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/00062	. . . . .	by genetic engineering
2750/14323	. . . . .	Virus like particles [VLP]	2760/00063	. . . . .	by chemical treatment
2750/14331	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/00064	. . . . .	by serial passage
2750/14332	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/00071	. . . . .	Demonstrated <u>in vivo</u> effect
2750/14333	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/00088	. . . . .	For redistribution
2750/14334	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/10011	. . . . .	Arenaviridae
2750/14341	. . . . .	Use of virus, viral particle or viral elements as a vector	2760/10021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2750/14342	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/10022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2760/10023	. . . . .	Virus like particles [VLP]

- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 . . . . viral genome or elements thereof as genetic vector
- 2760/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 . . . . Special targeting system for viral vectors
- 2760/10051 . . . Methods of production or purification of viral material
- 2760/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 . . . Methods of inactivation or attenuation
- 2760/10062 . . . . by genetic engineering
- 2760/10063 . . . . by chemical treatment
- 2760/10064 . . . . by serial passage
- 2760/10071 . . . Demonstrated in vivo effect
- 2760/10088 . . . For redistribution
- 2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
- 2760/10121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 . . . . Virus like particles [VLP]
- 2760/10131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/10142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 . . . . . viral genome or elements thereof as genetic vector
- 2760/10144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 . . . . . Special targeting system for viral vectors
- 2760/10151 . . . . Methods of production or purification of viral material
- 2760/10152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 . . . . Methods of inactivation or attenuation
- 2760/10162 . . . . . by genetic engineering
- 2760/10163 . . . . . by chemical treatment
- 2760/10164 . . . . . by serial passage
- 2760/10171 . . . . Demonstrated in vivo effect
- 2760/10188 . . . . For redistribution
- 2760/12011 . . . Bunyaviridae
- 2760/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 . . . . Virus like particles [VLP]
- 2760/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 . . . . . viral genome or elements thereof as genetic vector
- 2760/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 . . . . . Special targeting system for viral vectors
- 2760/12051 . . . . Methods of production or purification of viral material
- 2760/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 . . . . Methods of inactivation or attenuation
- 2760/12062 . . . . . by genetic engineering
- 2760/12063 . . . . . by chemical treatment
- 2760/12064 . . . . . by serial passage
- 2760/12071 . . . . Demonstrated in vivo effect
- 2760/12088 . . . . For redistribution
- 2760/12111 . . . . Hantavirus, e.g. Hantaan virus
- 2760/12121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 . . . . . Virus like particles [VLP]
- 2760/12131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 . . . . . Use of virus, viral particle or viral elements as a vector
- 2760/12142 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule

2760/12143	. . . .	viral genome or elements thereof as genetic vector	2760/14032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/14033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12145	. . . .	Special targeting system for viral vectors	2760/14034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12151	. . . .	Methods of production or purification of viral material	2760/14041	. . .	Use of virus, viral particle or viral elements as a vector
2760/12152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/14042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12161	. . . .	Methods of inactivation or attenuation	2760/14043	. . . .	viral genome or elements thereof as genetic vector
2760/12162	. . . .	by genetic engineering	2760/14044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12163	. . . .	by chemical treatment	2760/14045	. . . .	Special targeting system for viral vectors
2760/12164	. . . .	by serial passage	2760/14051	. . .	Methods of production or purification of viral material
2760/12171	. . . .	Demonstrated <u>in vivo</u> effect	2760/14052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/12188	. . . .	For redistribution	2760/14061	. . .	Methods of inactivation or attenuation
2760/12211	. . .	Phlebovirus, e.g. Rift Valley fever virus	2760/14062	. . . .	by genetic engineering
2760/12221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/14063	. . . .	by chemical treatment
2760/12222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/14064	. . . .	by serial passage
2760/12223	. . . .	Virus like particles [VLP]	2760/14071	. . .	Demonstrated <u>in vivo</u> effect
2760/12231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/14088	. . .	For redistribution
2760/12232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/14111	. . .	Ebolavirus, e.g. Zaire ebolavirus
2760/12233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/14121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/12234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/14122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/12241	. . . .	Use of virus, viral particle or viral elements as a vector	2760/14123	. . . .	Virus like particles [VLP]
2760/12242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/14131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/12243	. . . .	viral genome or elements thereof as genetic vector	2760/14132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/12244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/14133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/12245	. . . .	Special targeting system for viral vectors	2760/14134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/12251	. . . .	Methods of production or purification of viral material	2760/14141	. . . .	Use of virus, viral particle or viral elements as a vector
2760/12252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/14142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/12261	. . . .	Methods of inactivation or attenuation	2760/14143	. . . .	viral genome or elements thereof as genetic vector
2760/12262	. . . .	by genetic engineering	2760/14144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/12263	. . . .	by chemical treatment	2760/14145	. . . .	Special targeting system for viral vectors
2760/12264	. . . .	by serial passage	2760/14151	. . . .	Methods of production or purification of viral material
2760/12271	. . . .	Demonstrated <u>in vivo</u> effect	2760/14152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/12288	. . . .	For redistribution	2760/14161	. . . .	Methods of inactivation or attenuation
2760/14011	. .	Filoviridae	2760/14162	. . . .	by genetic engineering
2760/14021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/14163	. . . .	by chemical treatment
2760/14022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2760/14023	. . .	Virus like particles [VLP]			
2760/14031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			



- 2760/14164 . . . . by serial passage
- 2760/14171 . . . . Demonstrated in vivo effect
- 2760/14188 . . . . For redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 . . . . . viral genome or elements thereof as genetic vector
- 2760/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 . . . . . Special targeting system for viral vectors
- 2760/14251 . . . . Methods of production or purification of viral material
- 2760/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 . . . . Methods of inactivation or attenuation
- 2760/14262 . . . . . by genetic engineering
- 2760/14263 . . . . . by chemical treatment
- 2760/14264 . . . . . by serial passage
- 2760/14271 . . . . Demonstrated in vivo effect
- 2760/14288 . . . . For redistribution
- 2760/16011 . . . Orthomyxoviridae
- 2760/16021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 . . . . Virus like particles [VLP]
- 2760/16031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 . . . . . viral genome or elements thereof as genetic vector
- 2760/16044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 . . . . . Special targeting system for viral vectors
- 2760/16051 . . . . Methods of production or purification of viral material
- 2760/16052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 . . . . Methods of inactivation or attenuation
- 2760/16062 . . . . . by genetic engineering
- 2760/16063 . . . . . by chemical treatment
- 2760/16064 . . . . . by serial passage
- 2760/16071 . . . . Demonstrated in vivo effect
- 2760/16088 . . . . For redistribution
- 2760/16111 . . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 . . . . . Virus like particles [VLP]
- 2760/16131 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 . . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16142 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 . . . . . . viral genome or elements thereof as genetic vector
- 2760/16144 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 . . . . . . Special targeting system for viral vectors
- 2760/16151 . . . . . Methods of production or purification of viral material
- 2760/16152 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 . . . . . Methods of inactivation or attenuation
- 2760/16162 . . . . . . by genetic engineering
- 2760/16163 . . . . . . by chemical treatment
- 2760/16164 . . . . . . by serial passage
- 2760/16171 . . . . . Demonstrated in vivo effect
- 2760/16188 . . . . . For redistribution
- 2760/16211 . . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 . . . . . Virus like particles [VLP]
- 2760/16231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2760/16232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 . . . . . viral genome or elements thereof as genetic vector
- 2760/16244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 . . . . . Special targeting system for viral vectors
- 2760/16251 . . . . Methods of production or purification of viral material
- 2760/16252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 . . . . Methods of inactivation or attenuation
- 2760/16262 . . . . . by genetic engineering
- 2760/16263 . . . . . by chemical treatment
- 2760/16264 . . . . . by serial passage
- 2760/16271 . . . . Demonstrated in vivo effect
- 2760/16288 . . . . For redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 . . . . Virus like particles [VLP]
- 2760/16331 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16334 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/16342 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 . . . . . viral genome or elements thereof as genetic vector
- 2760/16344 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 . . . . . Special targeting system for viral vectors
- 2760/16351 . . . . Methods of production or purification of viral material
- 2760/16352 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 . . . . Methods of inactivation or attenuation
- 2760/16362 . . . . . by genetic engineering
- 2760/16363 . . . . . by chemical treatment
- 2760/16364 . . . . . by serial passage
- 2760/16371 . . . . Demonstrated in vivo effect
- 2760/16388 . . . . For redistribution
- 2760/18011 . . Paramyxoviridae
- 2760/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 . . . Virus like particles [VLP]
- 2760/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 . . . . viral genome or elements thereof as genetic vector
- 2760/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 . . . . Special targeting system for viral vectors
- 2760/18051 . . . Methods of production or purification of viral material
- 2760/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 . . . Methods of inactivation or attenuation
- 2760/18062 . . . . by genetic engineering
- 2760/18063 . . . . by chemical treatment
- 2760/18064 . . . . by serial passage
- 2760/18071 . . . Demonstrated in vivo effect
- 2760/18088 . . . For redistribution
- 2760/18111 . . . Avulavirus, e.g. Newcastle disease virus
- 2760/18121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 . . . . Virus like particles [VLP]
- 2760/18131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 . . . . Use of virus, viral particle or viral elements as a vector
- 2760/18142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 . . . . . viral genome or elements thereof as genetic vector

2760/18144	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/18333	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18145	. . . . .	Special targeting system for viral vectors	2760/18334	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18151	. . . . .	Methods of production or purification of viral material	2760/18341	. . . . .	Use of virus, viral particle or viral elements as a vector
2760/18152	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/18342	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18161	. . . . .	Methods of inactivation or attenuation	2760/18343	. . . . .	viral genome or elements thereof as genetic vector
2760/18162	. . . . .	by genetic engineering	2760/18344	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18163	. . . . .	by chemical treatment	2760/18345	. . . . .	Special targeting system for viral vectors
2760/18164	. . . . .	by serial passage	2760/18351	. . . . .	Methods of production or purification of viral material
2760/18171	. . . . .	Demonstrated <u>in vivo</u> effect	2760/18352	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18188	. . . . .	For redistribution	2760/18361	. . . . .	Methods of inactivation or attenuation
2760/18211	. . . . .	Henipavirus, e.g. hendra virus	2760/18362	. . . . .	by genetic engineering
2760/18221	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18363	. . . . .	by chemical treatment
2760/18222	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18364	. . . . .	by serial passage
2760/18223	. . . . .	Virus like particles [VLP]	2760/18371	. . . . .	Demonstrated <u>in vivo</u> effect
2760/18231	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/18388	. . . . .	For redistribution
2760/18232	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18411	. . . . .	Morbillivirus, e.g. Measles virus, canine distemper
2760/18233	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18421	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18234	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18422	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18241	. . . . .	Use of virus, viral particle or viral elements as a vector	2760/18423	. . . . .	Virus like particles [VLP]
2760/18242	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18431	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18243	. . . . .	viral genome or elements thereof as genetic vector	2760/18432	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18244	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/18433	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18245	. . . . .	Special targeting system for viral vectors	2760/18434	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18251	. . . . .	Methods of production or purification of viral material	2760/18441	. . . . .	Use of virus, viral particle or viral elements as a vector
2760/18252	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/18442	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18261	. . . . .	Methods of inactivation or attenuation	2760/18443	. . . . .	viral genome or elements thereof as genetic vector
2760/18262	. . . . .	by genetic engineering	2760/18444	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18263	. . . . .	by chemical treatment	2760/18445	. . . . .	Special targeting system for viral vectors
2760/18264	. . . . .	by serial passage	2760/18451	. . . . .	Methods of production or purification of viral material
2760/18271	. . . . .	Demonstrated <u>in vivo</u> effect	2760/18452	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18288	. . . . .	For redistribution	2760/18461	. . . . .	Methods of inactivation or attenuation
2760/18311	. . . . .	Metapneumovirus, e.g. avian pneumovirus	2760/18462	. . . . .	by genetic engineering
2760/18321	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18463	. . . . .	by chemical treatment
2760/18322	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18464	. . . . .	by serial passage
2760/18323	. . . . .	Virus like particles [VLP]			
2760/18331	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2760/18332	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

2760/18471	. . . .	Demonstrated <u>in vivo</u> effect	2760/18643	. . . .	viral genome or elements thereof as genetic vector
2760/18488	. . . .	For redistribution	2760/18644	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18511	. . . .	Pneumovirus, e.g. human respiratory syncytial virus	2760/18645	. . . .	Special targeting system for viral vectors
2760/18521	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18651	. . . .	Methods of production or purification of viral material
2760/18522	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18652	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18523	. . . .	Virus like particles [VLP]	2760/18661	. . . .	Methods of inactivation or attenuation
2760/18531	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/18662	. . . .	by genetic engineering
2760/18532	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18663	. . . .	by chemical treatment
2760/18533	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18664	. . . .	by serial passage
2760/18534	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18671	. . . .	Demonstrated <u>in vivo</u> effect
2760/18541	. . . .	Use of virus, viral particle or viral elements as a vector	2760/18688	. . . .	For redistribution
2760/18542	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18711	. . . .	Rubulavirus, e.g. mumps virus, parainfluenza 2,4
2760/18543	. . . .	viral genome or elements thereof as genetic vector	2760/18721	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18544	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/18722	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18545	. . . .	Special targeting system for viral vectors	2760/18723	. . . .	Virus like particles [VLP]
2760/18551	. . . .	Methods of production or purification of viral material	2760/18731	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18552	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/18732	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18561	. . . .	Methods of inactivation or attenuation	2760/18733	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18562	. . . .	by genetic engineering	2760/18734	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18563	. . . .	by chemical treatment	2760/18741	. . . .	Use of virus, viral particle or viral elements as a vector
2760/18564	. . . .	by serial passage	2760/18742	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18571	. . . .	Demonstrated <u>in vivo</u> effect	2760/18743	. . . .	viral genome or elements thereof as genetic vector
2760/18588	. . . .	For redistribution	2760/18744	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18611	. . . .	Respirovirus, e.g. Bovine, human parainfluenza 1,3	2760/18745	. . . .	Special targeting system for viral vectors
2760/18621	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/18751	. . . .	Methods of production or purification of viral material
2760/18622	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/18752	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/18623	. . . .	Virus like particles [VLP]	2760/18761	. . . .	Methods of inactivation or attenuation
2760/18631	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/18762	. . . .	by genetic engineering
2760/18632	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/18763	. . . .	by chemical treatment
2760/18633	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/18764	. . . .	by serial passage
2760/18634	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/18771	. . . .	Demonstrated <u>in vivo</u> effect
2760/18641	. . . .	Use of virus, viral particle or viral elements as a vector	2760/18788	. . . .	For redistribution
2760/18642	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/18811	. . . .	Sendai virus
			2760/18821	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
			2760/18822	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
			2760/18823	. . . .	Virus like particles [VLP]

2760/18831	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/20071	. . . .	Demonstrated <u>in vivo</u> effect
2760/18832	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/20088	. . . .	For redistribution
2760/18833	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/20111	. . . .	Lyssavirus, e.g. rabies virus
2760/18834	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/20121	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/18841	. . . .	Use of virus, viral particle or viral elements as a vector	2760/20122	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/18842	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/20123	. . . .	Virus like particles [VLP]
2760/18843	. . . .	viral genome or elements thereof as genetic vector	2760/20131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/18845	. . . .	Special targeting system for viral vectors	2760/20132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/18851	. . . .	Methods of production or purification of viral material	2760/20133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/18852	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/20134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/18861	. . . .	Methods of inactivation or attenuation	2760/20141	. . . .	Use of virus, viral particle or viral elements as a vector
2760/18862	. . . .	by genetic engineering	2760/20142	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/18863	. . . .	by chemical treatment	2760/20143	. . . .	viral genome or elements thereof as genetic vector
2760/18864	. . . .	by serial passage	2760/20144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/18871	. . . .	Demonstrated <u>in vivo</u> effect	2760/20145	. . . .	Special targeting system for viral vectors
2760/18888	. . . .	For redistribution	2760/20151	. . . .	Methods of production or purification of viral material
2760/20011	. .	Rhabdoviridae	2760/20152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2760/20021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2760/20161	. . . .	Methods of inactivation or attenuation
2760/20022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2760/20162	. . . .	by genetic engineering
2760/20023	. . .	Virus like particles [VLP]	2760/20163	. . . .	by chemical treatment
2760/20031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2760/20164	. . . .	by serial passage
2760/20032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2760/20171	. . . .	Demonstrated <u>in vivo</u> effect
2760/20033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2760/20188	. . . .	For redistribution
2760/20034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2760/20211	. . .	Vesiculovirus, e.g. vesicular stomatitis Indiana virus
2760/20041	. . .	Use of virus, viral particle or viral elements as a vector	2760/20221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2760/20042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2760/20222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2760/20043	. . . .	viral genome or elements thereof as genetic vector	2760/20223	. . . .	Virus like particles [VLP]
2760/20044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2760/20231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2760/20045	. . . .	Special targeting system for viral vectors	2760/20232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20051	. . .	Methods of production or purification of viral material	2760/20233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2760/20234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20061	. . .	Methods of inactivation or attenuation	2760/20241	. . . .	Use of virus, viral particle or viral elements as a vector
2760/20062	. . . .	by genetic engineering	2760/20242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20063	. . . .	by chemical treatment	2760/20243	. . . .	viral genome or elements thereof as genetic vector
2760/20064	. . . .	by serial passage			



2760/20244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2760/20245	. . . .	Special targeting system for viral vectors	2770/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2760/20251	. . . .	Methods of production or purification of viral material	2770/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2760/20252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/10041	. . .	Use of virus, viral particle or viral elements as a vector
2760/20261	. . . .	Methods of inactivation or attenuation	2770/10042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2760/20262	. . . .	by genetic engineering	2770/10043	. . . .	viral genome or elements thereof as genetic vector
2760/20263	. . . .	by chemical treatment	2770/10044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2760/20264	. . . .	by serial passage	2770/10045	. . . .	Special targeting system for viral vectors
2760/20271	. . . .	Demonstrated <u>in vivo</u> effect	2770/10051	. . .	Methods of production or purification of viral material
2760/20288	. . . .	For redistribution	2770/10052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
<b>2770/00</b>		<b>ssRNA Viruses positive-sense (not used)</b>	2770/10061	. . .	Methods of inactivation or attenuation
2770/00011	. . .	ssRNA Viruses positive-sense	2770/10062	. . . .	by genetic engineering
2770/00021	. .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/10063	. . . .	by chemical treatment
2770/00022	. .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/10064	. . . .	by serial passage
2770/00023	. .	Virus like particles [VLP]	2770/10071	. . .	Demonstrated <u>in vivo</u> effect
2770/00031	. .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/10088	. . .	For redistribution
2770/00032	. .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/12011	. .	Astroviridae
2770/00033	. .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/12021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/00034	. .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/12022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/00041	. .	Use of virus, viral particle or viral elements as a vector	2770/12023	. . .	Virus like particles [VLP]
2770/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/12031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/00043	. . .	viral genome or elements thereof as genetic vector	2770/12032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/12033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/00045	. . .	Special targeting system for viral vectors	2770/12034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/00051	. .	Methods of production or purification of viral material	2770/12041	. . .	Use of virus, viral particle or viral elements as a vector
2770/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/12042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/00061	. .	Methods of inactivation or attenuation	2770/12043	. . . .	viral genome or elements thereof as genetic vector
2770/00062	. . .	by genetic engineering	2770/12044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/00063	. . .	by chemical treatment	2770/12045	. . . .	Special targeting system for viral vectors
2770/00064	. . .	by serial passage	2770/12051	. . .	Methods of production or purification of viral material
2770/00071	. .	Demonstrated <u>in vivo</u> effect	2770/12052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/00088	. .	For redistribution	2770/12061	. . .	Methods of inactivation or attenuation
2770/10011	. .	Arteriviridae	2770/12062	. . . .	by genetic engineering
2770/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/12063	. . . .	by chemical treatment
2770/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2770/10023	. . .	Virus like particles [VLP]			
2770/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2770/12064 . . . . by serial passage
- 2770/12071 . . . . Demonstrated in vivo effect
- 2770/12088 . . . . For redistribution
- 2770/14011 . . . . Bromoviridae
- 2770/14021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 . . . . Virus like particles [VLP]
- 2770/14031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 . . . . viral genome or elements thereof as genetic vector
- 2770/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 . . . . Special targeting system for viral vectors
- 2770/14051 . . . . Methods of production or purification of viral material
- 2770/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 . . . . Methods of inactivation or attenuation
- 2770/14062 . . . . by genetic engineering
- 2770/14063 . . . . by chemical treatment
- 2770/14064 . . . . by serial passage
- 2770/14071 . . . . Demonstrated in vivo effect
- 2770/14088 . . . . For redistribution
- 2770/16011 . . . . Caliciviridae
- 2770/16021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . . Virus like particles [VLP]
- 2770/16031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 . . . . viral genome or elements thereof as genetic vector
- 2770/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 . . . . Special targeting system for viral vectors
- 2770/16051 . . . . Methods of production or purification of viral material
- 2770/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . . Methods of inactivation or attenuation
- 2770/16062 . . . . by genetic engineering
- 2770/16063 . . . . by chemical treatment
- 2770/16064 . . . . by serial passage
- 2770/16071 . . . . Demonstrated in vivo effect
- 2770/16088 . . . . For redistribution
- 2770/18011 . . . . Comoviridae
- 2770/18021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . . Virus like particles [VLP]
- 2770/18031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 . . . . viral genome or elements thereof as genetic vector
- 2770/18044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 . . . . Special targeting system for viral vectors
- 2770/18051 . . . . Methods of production or purification of viral material
- 2770/18052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . . Methods of inactivation or attenuation
- 2770/18062 . . . . by genetic engineering
- 2770/18063 . . . . by chemical treatment
- 2770/18064 . . . . by serial passage
- 2770/18071 . . . . Demonstrated in vivo effect
- 2770/18088 . . . . For redistribution
- 2770/20011 . . . . Coronaviridae
- 2770/20021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . . Virus like particles [VLP]
- 2770/20031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 . . . . viral genome or elements thereof as genetic vector
- 2770/20044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 . . . . Special targeting system for viral vectors
- 2770/20051 . . . Methods of production or purification of viral material
- 2770/20052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . Methods of inactivation or attenuation
- 2770/20062 . . . . by genetic engineering
- 2770/20063 . . . . by chemical treatment
- 2770/20064 . . . . by serial passage
- 2770/20071 . . . Demonstrated in vivo effect
- 2770/20088 . . . For redistribution
- 2770/22011 . . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 . . . . viral genome or elements thereof as genetic vector
- 2770/22044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 . . . . Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 . . . . by genetic engineering
- 2770/22063 . . . . by chemical treatment
- 2770/22064 . . . . by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . For redistribution
- 2770/24011 . . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 . . . . viral genome or elements thereof as genetic vector
- 2770/24044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 . . . . Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 . . . . by genetic engineering
- 2770/24063 . . . . by chemical treatment
- 2770/24064 . . . . by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . For redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 . . . . Virus like particles [VLP]
- 2770/24131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/24142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 . . . . . viral genome or elements thereof as genetic vector

2770/24144	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/24332	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/24145	. . . .	Special targeting system for viral vectors	2770/24333	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/24151	. . . .	Methods of production or purification of viral material	2770/24334	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/24152	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/24341	. . . .	Use of virus, viral particle or viral elements as a vector
2770/24161	. . . .	Methods of inactivation or attenuation	2770/24342	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/24162	. . . .	by genetic engineering	2770/24343	. . . .	viral genome or elements thereof as genetic vector
2770/24163	. . . .	by chemical treatment	2770/24344	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/24164	. . . .	by serial passage	2770/24345	. . . .	Special targeting system for viral vectors
2770/24171	. . . .	Demonstrated <u>in vivo</u> effect	2770/24351	. . . .	Methods of production or purification of viral material
2770/24188	. . . .	For redistribution	2770/24352	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/24211	. . .	Hepacivirus, e.g. hepatitis C virus, hepatitis G virus	2770/24361	. . . .	Methods of inactivation or attenuation
2770/24221	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/24362	. . . .	by genetic engineering
2770/24222	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/24363	. . . .	by chemical treatment
2770/24223	. . . .	Virus like particles [VLP]	2770/24364	. . . .	by serial passage
2770/24231	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/24371	. . . .	Demonstrated <u>in vivo</u> effect
2770/24232	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/24388	. . . .	For redistribution
2770/24233	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/26011	. .	Flexiviridae
2770/24234	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/26021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/24241	. . . .	Use of virus, viral particle or viral elements as a vector	2770/26022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/24242	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/26023	. . .	Virus like particles [VLP]
2770/24243	. . . .	viral genome or elements thereof as genetic vector	2770/26031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/24244	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/26032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/24245	. . . .	Special targeting system for viral vectors	2770/26033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/24251	. . . .	Methods of production or purification of viral material	2770/26034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/24252	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/26041	. . .	Use of virus, viral particle or viral elements as a vector
2770/24261	. . . .	Methods of inactivation or attenuation	2770/26042	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/24262	. . . .	by genetic engineering	2770/26043	. . . .	viral genome or elements thereof as genetic vector
2770/24263	. . . .	by chemical treatment	2770/26044	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/24264	. . . .	by serial passage	2770/26045	. . . .	Special targeting system for viral vectors
2770/24271	. . . .	Demonstrated <u>in vivo</u> effect	2770/26051	. . .	Methods of production or purification of viral material
2770/24288	. . . .	For redistribution	2770/26052	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/24311	. . .	Pestivirus, e.g. bovine viral diarrhea virus	2770/26061	. . .	Methods of inactivation or attenuation
2770/24321	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/26062	. . . .	by genetic engineering
2770/24322	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/26063	. . . .	by chemical treatment
2770/24323	. . . .	Virus like particles [VLP]			
2770/24331	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			

- 2770/26064 . . . . by serial passage
- 2770/26071 . . . Demonstrated in vivo effect
- 2770/26088 . . . For redistribution
- 2770/28011 . . . Hepeviridae
- 2770/28021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 . . . Virus like particles [VLP]
- 2770/28031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/28042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 . . . . viral genome or elements thereof as genetic vector
- 2770/28044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 . . . . Special targeting system for viral vectors
- 2770/28051 . . . Methods of production or purification of viral material
- 2770/28052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 . . . Methods of inactivation or attenuation
- 2770/28062 . . . . by genetic engineering
- 2770/28063 . . . . by chemical treatment
- 2770/28064 . . . . by serial passage
- 2770/28071 . . . Demonstrated in vivo effect
- 2770/28088 . . . For redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 . . . . Virus like particles [VLP]
- 2770/28131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/28142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 . . . . . viral genome or elements thereof as genetic vector
- 2770/28144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 . . . . . Special targeting system for viral vectors
- 2770/28151 . . . . Methods of production or purification of viral material
- 2770/28152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 . . . . Methods of inactivation or attenuation
- 2770/28162 . . . . . by genetic engineering
- 2770/28163 . . . . . by chemical treatment
- 2770/28164 . . . . . by serial passage
- 2770/28171 . . . . Demonstrated in vivo effect
- 2770/28188 . . . . For redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 . . . Virus like particles [VLP]
- 2770/30031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/30033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/30042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 . . . . viral genome or elements thereof as genetic vector
- 2770/30044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 . . . . Special targeting system for viral vectors
- 2770/30051 . . . Methods of production or purification of viral material
- 2770/30052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 . . . Methods of inactivation or attenuation
- 2770/30062 . . . . by genetic engineering
- 2770/30063 . . . . by chemical treatment
- 2770/30064 . . . . by serial passage
- 2770/30071 . . . Demonstrated in vivo effect
- 2770/30088 . . . For redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 . . . Virus like particles [VLP]
- 2770/32031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent



- 2770/32033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/32042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 . . . . viral genome or elements thereof as genetic vector
- 2770/32044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 . . . . Special targeting system for viral vectors
- 2770/32051 . . . Methods of production or purification of viral material
- 2770/32052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 . . . Methods of inactivation or attenuation
- 2770/32062 . . . . by genetic engineering
- 2770/32063 . . . . by chemical treatment
- 2770/32064 . . . . by serial passage
- 2770/32071 . . . Demonstrated in vivo effect
- 2770/32088 . . . For redistribution
- 2770/32111 . . . Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 . . . . Virus like particles [VLP]
- 2770/32131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 . . . . . viral genome or elements thereof as genetic vector
- 2770/32144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 . . . . . Special targeting system for viral vectors
- 2770/32151 . . . . Methods of production or purification of viral material
- 2770/32152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 . . . . Methods of inactivation or attenuation
- 2770/32162 . . . . . by genetic engineering
- 2770/32163 . . . . . by chemical treatment
- 2770/32164 . . . . . by serial passage
- 2770/32171 . . . . Demonstrated in vivo effect
- 2770/32188 . . . . For redistribution
- 2770/32211 . . . . Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 . . . . . Virus like particles [VLP]
- 2770/32231 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32242 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 . . . . . . viral genome or elements thereof as genetic vector
- 2770/32244 . . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 . . . . . . Special targeting system for viral vectors
- 2770/32251 . . . . . Methods of production or purification of viral material
- 2770/32252 . . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 . . . . . Methods of inactivation or attenuation
- 2770/32262 . . . . . . by genetic engineering
- 2770/32263 . . . . . . by chemical treatment
- 2770/32264 . . . . . . by serial passage
- 2770/32271 . . . . . Demonstrated in vivo effect
- 2770/32288 . . . . . For redistribution
- 2770/32311 . . . . Enterovirus
- 2770/32321 . . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 . . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 . . . . . Virus like particles [VLP]
- 2770/32331 . . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 . . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 . . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 . . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 . . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32342 . . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 . . . . . . viral genome or elements thereof as genetic vector

2770/32344	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32533	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32345	. . . .	Special targeting system for viral vectors	2770/32534	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32351	. . . .	Methods of production or purification of viral material	2770/32541	. . . .	Use of virus, viral particle or viral elements as a vector
2770/32352	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32542	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32361	. . . .	Methods of inactivation or attenuation	2770/32543	. . . .	viral genome or elements thereof as genetic vector
2770/32362	. . . .	by genetic engineering	2770/32544	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32363	. . . .	by chemical treatment	2770/32545	. . . .	Special targeting system for viral vectors
2770/32364	. . . .	by serial passage	2770/32551	. . . .	Methods of production or purification of viral material
2770/32371	. . . .	Demonstrated <u>in vivo</u> effect	2770/32552	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32388	. . . .	For redistribution	2770/32561	. . . .	Methods of inactivation or attenuation
2770/32411	. . .	Hepatovirus, i.e. hepatitis A virus	2770/32562	. . . .	by genetic engineering
2770/32421	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32563	. . . .	by chemical treatment
2770/32422	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32564	. . . .	by serial passage
2770/32423	. . . .	Virus like particles [VLP]	2770/32571	. . . .	Demonstrated <u>in vivo</u> effect
2770/32431	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2770/32588	. . . .	For redistribution
2770/32432	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2770/32611	. . .	Poliovirus
2770/32433	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2770/32621	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2770/32434	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2770/32622	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2770/32441	. . . .	Use of virus, viral particle or viral elements as a vector	2770/32623	. . . .	Virus like particles [VLP]
2770/32442	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2770/32631	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2770/32443	. . . .	viral genome or elements thereof as genetic vector	2770/32632	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2770/32444	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2770/32633	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2770/32445	. . . .	Special targeting system for viral vectors	2770/32634	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2770/32451	. . . .	Methods of production or purification of viral material	2770/32641	. . . .	Use of virus, viral particle or viral elements as a vector
2770/32452	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2770/32642	. . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2770/32461	. . . .	Methods of inactivation or attenuation	2770/32643	. . . .	viral genome or elements thereof as genetic vector
2770/32462	. . . .	by genetic engineering	2770/32644	. . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2770/32463	. . . .	by chemical treatment	2770/32645	. . . .	Special targeting system for viral vectors
2770/32464	. . . .	by serial passage	2770/32651	. . . .	Methods of production or purification of viral material
2770/32471	. . . .	Demonstrated <u>in vivo</u> effect	2770/32652	. . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2770/32488	. . . .	For redistribution	2770/32661	. . . .	Methods of inactivation or attenuation
2770/32511	. . .	Parechovirus, e.g. human parechovirus	2770/32662	. . . .	by genetic engineering
2770/32521	. . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2770/32663	. . . .	by chemical treatment
2770/32522	. . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2770/32664	. . . .	by serial passage
2770/32523	. . . .	Virus like particles [VLP]	2770/32671	. . . .	Demonstrated <u>in vivo</u> effect
2770/32531	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant			
2770/32532	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent			

- 2770/32688 . . . . For redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 . . . . Virus like particles [VLP]
- 2770/32731 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/32742 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 . . . . viral genome or elements thereof as genetic vector
- 2770/32744 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 . . . . Special targeting system for viral vectors
- 2770/32751 . . . . Methods of production or purification of viral material
- 2770/32752 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 . . . . Methods of inactivation or attenuation
- 2770/32762 . . . . by genetic engineering
- 2770/32763 . . . . by chemical treatment
- 2770/32764 . . . . by serial passage
- 2770/32771 . . . . Demonstrated in vivo effect
- 2770/32788 . . . . For redistribution
- 2770/34011 . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 . . . viral genome or elements thereof as genetic vector
- 2770/34044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 . . . . Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 . . . . by genetic engineering
- 2770/34063 . . . . by chemical treatment
- 2770/34064 . . . . by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . For redistribution
- 2770/36011 . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 . . . . viral genome or elements thereof as genetic vector
- 2770/36044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 . . . . Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 . . . . by genetic engineering
- 2770/36063 . . . . by chemical treatment
- 2770/36064 . . . . by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . For redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 . . . . Virus like particles [VLP]
- 2770/36131 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/36132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 . . . . . viral genome or elements thereof as genetic vector
- 2770/36144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 . . . . . Special targeting system for viral vectors
- 2770/36151 . . . . Methods of production or purification of viral material
- 2770/36152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 . . . . Methods of inactivation or attenuation
- 2770/36162 . . . . . by genetic engineering
- 2770/36163 . . . . . by chemical treatment
- 2770/36164 . . . . . by serial passage
- 2770/36171 . . . . Demonstrated in vivo effect
- 2770/36188 . . . . For redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 . . . . Virus like particles [VLP]
- 2770/36231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 . . . . Use of virus, viral particle or viral elements as a vector
- 2770/36242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 . . . . . viral genome or elements thereof as genetic vector
- 2770/36244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 . . . . . Special targeting system for viral vectors
- 2770/36251 . . . . Methods of production or purification of viral material
- 2770/36252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 . . . . Methods of inactivation or attenuation
- 2770/36262 . . . . . by genetic engineering
- 2770/36263 . . . . . by chemical treatment
- 2770/36264 . . . . . by serial passage
- 2770/36271 . . . . Demonstrated in vivo effect
- 2770/36288 . . . . For redistribution
- 2770/38011 . . . Tombusviridae
- 2770/38021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 . . . Virus like particles [VLP]
- 2770/38031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/38042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 . . . . viral genome or elements thereof as genetic vector
- 2770/38044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 . . . . Special targeting system for viral vectors
- 2770/38051 . . . Methods of production or purification of viral material
- 2770/38052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 . . . Methods of inactivation or attenuation
- 2770/38062 . . . . by genetic engineering
- 2770/38063 . . . . by chemical treatment
- 2770/38064 . . . . by serial passage
- 2770/38071 . . . Demonstrated in vivo effect
- 2770/38088 . . . For redistribution
- 2770/40011 . . . Tymoviridae
- 2770/40021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 . . . Virus like particles [VLP]
- 2770/40031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/40042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 . . . . viral genome or elements thereof as genetic vector

- 2770/40044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 . . . . Special targeting system for viral vectors
- 2770/40051 . . . . Methods of production or purification of viral material
- 2770/40052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 . . . . Methods of inactivation or attenuation
- 2770/40062 . . . . by genetic engineering
- 2770/40063 . . . . by chemical treatment
- 2770/40064 . . . . by serial passage
- 2770/40071 . . . . Demonstrated in vivo effect
- 2770/40088 . . . . For redistribution
- 2780/00** **Naked RNA Viruses (not used)**
- 2780/00011 . . . . Naked RNA Viruses
- 2780/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 . . . . Virus like particles [VLP]
- 2780/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 . . . . Use of virus, viral particle or viral elements as a vector
- 2780/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/00043 . . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . . Special targeting system for viral vectors
- 2780/00051 . . . . Methods of production or purification of viral material
- 2780/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . . . Methods of inactivation or attenuation
- 2780/00062 . . . . by genetic engineering
- 2780/00063 . . . . by chemical treatment
- 2780/00064 . . . . by serial passage
- 2780/00071 . . . . Demonstrated in vivo effect
- 2780/00088 . . . . For redistribution
- 2780/10011 . . . . Narnaviridae
- 2780/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . . Virus like particles [VLP]
- 2780/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 . . . . viral genome or elements thereof as genetic vector
- 2780/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 . . . . Special targeting system for viral vectors
- 2780/10051 . . . . Methods of production or purification of viral material
- 2780/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 . . . . Methods of inactivation or attenuation
- 2780/10062 . . . . by genetic engineering
- 2780/10063 . . . . by chemical treatment
- 2780/10064 . . . . by serial passage
- 2780/10071 . . . . Demonstrated in vivo effect
- 2780/10088 . . . . For redistribution
- 2790/00** **Viroids and subviral agents (not used)**
- 2790/00011 . . . . Viroids and subviral agents
- 2790/00021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . . . Virus like particles [VLP]
- 2790/00031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 . . . . viral genome or elements thereof as genetic vector
- 2790/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 . . . . Special targeting system for viral vectors
- 2790/00051 . . . . Methods of production or purification of viral material
- 2790/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . . . Methods of inactivation or attenuation
- 2790/00062 . . . . by genetic engineering



- 2790/00063 . . . by chemical treatment
- 2790/00064 . . . by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . For redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 . . . . viral genome or elements thereof as genetic vector
- 2790/10044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 . . . . Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 . . . . by genetic engineering
- 2790/10063 . . . . by chemical treatment
- 2790/10064 . . . . by serial passage
- 2790/10071 . . . Demonstrated in vivo effect
- 2790/10088 . . . For redistribution
- 2790/12011 . . Satellite viruses
- 2790/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 . . . Virus like particles [VLP]
- 2790/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/12042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 . . . . viral genome or elements thereof as genetic vector
- 2790/12044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 . . . . Special targeting system for viral vectors
- 2790/12051 . . . Methods of production or purification of viral material
- 2790/12052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 . . . Methods of inactivation or attenuation
- 2790/12062 . . . . by genetic engineering
- 2790/12063 . . . . by chemical treatment
- 2790/12064 . . . . by serial passage
- 2790/12071 . . . Demonstrated in vivo effect
- 2790/12088 . . . For redistribution
- 2790/14011 . . Viroids
- 2790/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 . . . Virus like particles [VLP]
- 2790/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/14042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 . . . . viral genome or elements thereof as genetic vector
- 2790/14044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 . . . . Special targeting system for viral vectors
- 2790/14051 . . . Methods of production or purification of viral material
- 2790/14052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 . . . Methods of inactivation or attenuation
- 2790/14062 . . . . by genetic engineering
- 2790/14063 . . . . by chemical treatment
- 2790/14064 . . . . by serial passage
- 2790/14071 . . . Demonstrated in vivo effect
- 2790/14088 . . . For redistribution
- 2792/00** **Archaeobacteria viruses (not used)**
- 2792/00011 . Archaeobacteria viruses
- 2792/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 . . Virus like particles [VLP]

- 2792/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/00042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 . . . . viral genome or elements thereof as genetic vector
- 2792/00044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 . . . . Special targeting system for viral vectors
- 2792/00051 . . . Methods of production or purification of viral material
- 2792/00052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 . . . Methods of inactivation or attenuation
- 2792/00062 . . . . by genetic engineering
- 2792/00063 . . . . by chemical treatment
- 2792/00064 . . . . by serial passage
- 2792/00071 . . . Demonstrated in vivo effect
- 2792/00088 . . . For redistribution
- 2792/10011 . . . Fuselloviridae
- 2792/10021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 . . . . Virus like particles [VLP]
- 2792/10031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 . . . . . viral genome or elements thereof as genetic vector
- 2792/10044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 . . . . . Special targeting system for viral vectors
- 2792/10051 . . . . Methods of production or purification of viral material
- 2792/10052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . . Methods of inactivation or attenuation
- 2792/10062 . . . . . by genetic engineering
- 2792/10063 . . . . . by chemical treatment
- 2792/10064 . . . . . by serial passage
- 2792/10071 . . . . Demonstrated in vivo effect
- 2792/10088 . . . . For redistribution
- 2792/12011 . . . Guttaviridae
- 2792/12021 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . . Virus like particles [VLP]
- 2792/12031 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 . . . . . viral genome or elements thereof as genetic vector
- 2792/12044 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 . . . . . Special targeting system for viral vectors
- 2792/12051 . . . . Methods of production or purification of viral material
- 2792/12052 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . . Methods of inactivation or attenuation
- 2792/12062 . . . . . by genetic engineering
- 2792/12063 . . . . . by chemical treatment
- 2792/12064 . . . . . by serial passage
- 2792/12071 . . . . Demonstrated in vivo effect
- 2792/12088 . . . . For redistribution
- 2795/00** **Bacteriophages (not used)**
- 2795/00011 . . Bacteriophages
- 2795/00021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . . Virus like particles [VLP]
- 2795/00031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . . Use of virus, viral particle or viral elements as a vector

2795/00042	. . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/10131	. . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/00043	. . .	viral genome or elements thereof as genetic vector	2795/10132	. . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/00044	. . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/10133	. . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/00045	. . .	Special targeting system for viral vectors	2795/10134	. . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/00051	. .	Methods of production or purification of viral material	2795/10141	. . . .	Use of virus, viral particle or viral elements as a vector
2795/00052	. . .	relating to complementing cells and packaging systems for producing virus or viral particles	2795/10142	. . . .	. virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/00061	. .	Methods of inactivation or attenuation	2795/10143	. . . .	. viral genome or elements thereof as genetic vector
2795/00062	. . .	by genetic engineering	2795/10144	. . . .	. Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/00063	. . .	by chemical treatment	2795/10145	. . . .	. Special targeting system for viral vectors
2795/00064	. . .	by serial passage	2795/10151	. . . .	. Methods of production or purification of viral material
2795/00071	. .	Demonstrated <u>in vivo</u> effect	2795/10152	. . . .	. relating to complementing cells and packaging systems for producing virus or viral particles
2795/00088	. .	For redistribution	2795/10161	. . . .	. Methods of inactivation or attenuation
2795/10011	. .	dsDNA Bacteriophages	2795/10162	. . . .	. by genetic engineering
2795/10021	. . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/10163	. . . .	. by chemical treatment
2795/10022	. . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2795/10164	. . . .	. by serial passage
2795/10023	. . .	Virus like particles [VLP]	2795/10171	. . . .	. Demonstrated <u>in vivo</u> effect
2795/10031	. . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2795/10188	. . . .	. For redistribution
2795/10032	. . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2795/10211	. . .	. Podoviridae
2795/10033	. . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2795/10221	. . . .	. Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10034	. . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2795/10222	. . . .	. New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10041	. . .	Use of virus, viral particle or viral elements as a vector	2795/10223	. . . .	. Virus like particles [VLP]
2795/10042	. . . .	. virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/10231	. . . .	. Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10043	. . . .	. viral genome or elements thereof as genetic vector	2795/10232	. . . .	. Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10044	. . . .	. Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/10233	. . . .	. Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10045	. . . .	. Special targeting system for viral vectors	2795/10234	. . . .	. Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10051	. . .	Methods of production or purification of viral material	2795/10241	. . . .	. Use of virus, viral particle or viral elements as a vector
2795/10052	. . . .	. relating to complementing cells and packaging systems for producing virus or viral particles	2795/10242	. . . .	. virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10061	. . .	Methods of inactivation or attenuation	2795/10243	. . . .	. viral genome or elements thereof as genetic vector
2795/10062	. . . .	. by genetic engineering	2795/10244	. . . .	. Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10063	. . . .	. by chemical treatment	2795/10245	. . . .	. Special targeting system for viral vectors
2795/10064	. . . .	. by serial passage	2795/10251	. . . .	. Methods of production or purification of viral material
2795/10071	. . .	Demonstrated <u>in vivo</u> effect	2795/10252	. . . .	. relating to complementing cells and packaging systems for producing virus or viral particles
2795/10088	. . .	For redistribution	2795/10261	. . . .	. Methods of inactivation or attenuation
2795/10111	. . .	Myoviridae			
2795/10121	. . . .	. Viruses as such, e.g. new isolates, mutants or their genomic sequences			
2795/10122	. . . .	. New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes			
2795/10123	. . . .	. Virus like particles [VLP]			

2795/10262	. . . . .	by genetic engineering	2795/12043	. . . . .	viral genome or elements thereof as genetic vector
2795/10263	. . . . .	by chemical treatment	2795/12044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10264	. . . . .	by serial passage	2795/12045	. . . . .	Special targeting system for viral vectors
2795/10271	. . . . .	Demonstrated <u>in vivo</u> effect	2795/12051	. . . . .	Methods of production or purification of viral material
2795/10288	. . . . .	For redistribution	2795/12052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2795/10311	. . . . .	Siphoviridae	2795/12061	. . . . .	Methods of inactivation or attenuation
2795/10321	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/12062	. . . . .	by genetic engineering
2795/10322	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2795/12063	. . . . .	by chemical treatment
2795/10323	. . . . .	Virus like particles [VLP]	2795/12064	. . . . .	by serial passage
2795/10331	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2795/12071	. . . . .	Demonstrated <u>in vivo</u> effect
2795/10332	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2795/12088	. . . . .	For redistribution
2795/10333	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2795/14011	. . . . .	ssDNA Bacteriophages
2795/10334	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2795/14021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/10341	. . . . .	Use of virus, viral particle or viral elements as a vector	2795/14022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/10342	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/14023	. . . . .	Virus like particles [VLP]
2795/10343	. . . . .	viral genome or elements thereof as genetic vector	2795/14031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant
2795/10344	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2795/14032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
2795/10345	. . . . .	Special targeting system for viral vectors	2795/14033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
2795/10351	. . . . .	Methods of production or purification of viral material	2795/14034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
2795/10352	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles	2795/14041	. . . . .	Use of virus, viral particle or viral elements as a vector
2795/10361	. . . . .	Methods of inactivation or attenuation	2795/14042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule
2795/10362	. . . . .	by genetic engineering	2795/14043	. . . . .	viral genome or elements thereof as genetic vector
2795/10363	. . . . .	by chemical treatment	2795/14044	. . . . .	Chimeric viral vector comprising heterologous viral elements for production of another viral vector
2795/10364	. . . . .	by serial passage	2795/14045	. . . . .	Special targeting system for viral vectors
2795/10371	. . . . .	Demonstrated <u>in vivo</u> effect	2795/14051	. . . . .	Methods of production or purification of viral material
2795/10388	. . . . .	For redistribution	2795/14052	. . . . .	relating to complementing cells and packaging systems for producing virus or viral particles
2795/12011	. . . . .	dsRNA Bacteriophages	2795/14061	. . . . .	Methods of inactivation or attenuation
2795/12021	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences	2795/14062	. . . . .	by genetic engineering
2795/12022	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2795/14063	. . . . .	by chemical treatment
2795/12023	. . . . .	Virus like particles [VLP]	2795/14064	. . . . .	by serial passage
2795/12031	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2795/14071	. . . . .	Demonstrated <u>in vivo</u> effect
2795/12032	. . . . .	Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2795/14088	. . . . .	For redistribution
2795/12033	. . . . .	Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2795/14111	. . . . .	Inoviridae
2795/12034	. . . . .	Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2795/14121	. . . . .	Viruses as such, e.g. new isolates, mutants or their genomic sequences
2795/12041	. . . . .	Use of virus, viral particle or viral elements as a vector	2795/14122	. . . . .	New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
2795/12042	. . . . .	virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2795/14123	. . . . .	Virus like particles [VLP]
			2795/14131	. . . . .	Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/14132 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14142 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 . . . . . viral genome or elements thereof as genetic vector
- 2795/14144 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 . . . . . Special targeting system for viral vectors
- 2795/14151 . . . . Methods of production or purification of viral material
- 2795/14152 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 . . . . Methods of inactivation or attenuation
- 2795/14162 . . . . . by genetic engineering
- 2795/14163 . . . . . by chemical treatment
- 2795/14164 . . . . . by serial passage
- 2795/14171 . . . . Demonstrated in vivo effect
- 2795/14188 . . . . For redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 . . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 . . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 . . . . Virus like particles [VLP]
- 2795/14231 . . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14232 . . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14233 . . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 . . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 . . . . Use of virus, viral particle or viral elements as a vector
- 2795/14242 . . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 . . . . . viral genome or elements thereof as genetic vector
- 2795/14244 . . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 . . . . . Special targeting system for viral vectors
- 2795/14251 . . . . Methods of production or purification of viral material
- 2795/14252 . . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 . . . . Methods of inactivation or attenuation
- 2795/14262 . . . . . by genetic engineering
- 2795/14263 . . . . . by chemical treatment
- 2795/14264 . . . . . by serial passage
- 2795/14271 . . . . Demonstrated in vivo effect
- 2795/14288 . . . . For redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 . . . . viral genome or elements thereof as genetic vector
- 2795/16044 . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 . . . . Special targeting system for viral vectors
- 2795/16051 . . . Methods of production or purification of viral material
- 2795/16052 . . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 . . . Methods of inactivation or attenuation
- 2795/16062 . . . . by genetic engineering
- 2795/16063 . . . . by chemical treatment
- 2795/16064 . . . . by serial passage
- 2795/16071 . . . Demonstrated in vivo effect
- 2795/16088 . . . For redistribution
- 2795/18011 . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 . . . Virus like particles [VLP]
- 2795/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/18042 . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 . . . . viral genome or elements thereof as genetic vector

2795/18044	. . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2799/021	. . for the expression of a heterologous nucleic acid
2795/18045	. . . . Special targeting system for viral vectors	2799/022	. . . where the vector is derived from an adenovirus
2795/18051	. . . Methods of production or purification of viral material	2799/023	. . . where the vector is derived from a poxvirus
2795/18052	. . . . relating to complementing cells and packaging systems for producing virus or viral particles	2799/025	. . . where the vector is derived from a parvovirus
2795/18061	. . . Methods of inactivation or attenuation	2799/026	. . . where the vector is derived from a baculovirus
2795/18062	. . . . by genetic engineering	2799/027	. . . where the vector is derived from a retrovirus
2795/18063	. . . . by chemical treatment	2799/028	. . . where the vector is derived from a herpesvirus
2795/18064	. . . . by serial passage	2799/04	. . <u>in vivo</u>
2795/18071	. . . Demonstrated <u>in vivo</u> effect	2799/06	. . <u>in vitro</u>
2795/18088	. . . For redistribution		
2795/18111	. . . Leviviridae	<b>2800/00</b>	<b>Nucleic acids vectors</b>
2795/18121	. . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences	2800/10	. Plasmid DNA
2795/18122	. . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes	2800/101	. . for bacteria
2795/18123	. . . . Virus like particles [VLP]	2800/102	. . for yeast
2795/18131	. . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant	2800/103	. . for invertebrates
2795/18132	. . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent	2800/105	. . . for insects
2795/18133	. . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory	2800/106	. . for vertebrates
2795/18134	. . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein	2800/107	. . . for mammalian
2795/18141	. . . . Use of virus, viral particle or viral elements as a vector	2800/108	. . episomal vectors
2795/18142	. . . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule	2800/20	. Pseudochromosomes, minichromosomes
2795/18143	. . . . . viral genome or elements thereof as genetic vector	2800/202	. . of bacteriophage origin
2795/18144	. . . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector	2800/204	. . of bacterial origin, e.g. BAC
2795/18145	. . . . . Special targeting system for viral vectors	2800/206	. . of yeast origin, e.g. YAC, 2u
2795/18151	. . . . Methods of production or purification of viral material	2800/208	. . of mammalian origin, e.g. minichromosome
2795/18152	. . . . . relating to complementing cells and packaging systems for producing virus or viral particles	2800/22	. Vectors comprising a coding region that has been codon optimised for expression in a respective host
2795/18161	. . . . Methods of inactivation or attenuation	2800/24	. Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
2795/18162	. . . . . by genetic engineering	2800/30	. Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
2795/18163	. . . . . by chemical treatment	2800/40	. Systems of functionally co-operating vectors
2795/18164	. . . . . by serial passage	2800/50	. Vectors for producing vectors
2795/18171	. . . . Demonstrated <u>in vivo</u> effect	2800/60	. Vectors containing traps for, e.g. exons, promoters
2795/18188	. . . . For redistribution	2800/70	. Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
<b>2799/00</b>	<b>Uses of viruses</b>	2800/80	. Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
	<b><u>WARNING</u></b>	2800/90	. Vectors containing a transposable element
	From March 15, 2012 codes in the range <a href="#">C12N 2799/00</a> - <a href="#">C12N 2799/06</a> are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in <a href="#">C12N 2710/00</a> - <a href="#">C12N 2795/00</a>	2800/95	. Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
2799/02	. as vector	<b>2810/00</b>	<b>Vectors comprising a targeting moiety</b>
		2810/10	. Vectors comprising a non-peptidic targeting moiety
		2810/40	. Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
		2810/405	. . Vectors comprising RGD peptide
		2810/50	. Vectors comprising as targeting moiety peptide derived from defined protein
		2810/55	. . from bacteria
		2810/60	. . from viruses
		2810/6009	. . . dsDNA viruses
		2810/6018	. . . . Adenoviridae
		2810/6027	. . . ssDNA viruses
		2810/6036	. . . DNA rev transcr viruses
		2810/6045	. . . RNA rev transcr viruses
		2810/6054	. . . . Retroviridae
		2810/6063	. . . ds RNA viruses
		2810/6072	. . . negative strand RNA viruses
		2810/6081	. . . . rhabdoviridae, e.g. VSV
		2810/609	. . . positive strand RNA viruses
		2810/65	. . from plants
		2810/70	. . from fungi



2810/75	. . from invertebrates
2810/80	. . from vertebrates
2810/85	. . . mammalian
2810/851	. . . . from growth factors; from growth regulators
2810/852	. . . . from cytokines; from lymphokines; from interferons
2810/853	. . . . . from tumor necrosis factor, TNF
2810/854	. . . . from hormones
2810/855	. . . . from receptors; from cell surface antigens; from cell surface determinants
2810/856	. . . . . from integrins
2810/857	. . . . from blood coagulation or fibrinolysis factors
2810/858	. . . . from apolipoproteins
2810/859	. . . . from immunoglobulins
2810/90	. . . avian

#### **2820/00 Vectors comprising a special origin of replication system**

2820/002	. inducible or controllable
2820/005	. cell-cycle regulated
2820/007	. tissue or cell-specific
2820/10	. multiple origins of replication
2820/55	. from bacteria
2820/60	. from viruses
2820/65	. from plants
2820/70	. from fungi
2820/702	. . yeast
2820/704	. . . S. cerevisiae
2820/706	. . . S. pombe
2820/708	. . . C. albicans
2820/75	. from invertebrates
2820/80	. from vertebrates
2820/85	. . mammalian
2820/90	. . avian

#### **2830/00 Vector systems having a special element relevant for transcription**

2830/001	. controllable enhancer/promoter combination
2830/002	. . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
2830/003	. . . tet inducible
2830/005	. . repressible enhancer/promoter combination, e.g. KRAB
2830/006	. . . tet repressible
2830/007	. cell cycle specific enhancer/promoter combination
2830/008	. cell type or tissue specific enhancer/promoter combination
2830/15	. chimeric enhancer/promoter combination
2830/20	. transcription of more than one cistron
2830/205	. . bidirectional
2830/30	. being an enhancer not forming part of the promoter region
2830/32	. being an silencer not forming part of the promoter region
2830/34	. being a transcription initiation element
2830/36	. being a transcription termination element
2830/38	. being a stuffer
2830/40	. being an insulator
2830/42	. being an intron or intervening sequence for splicing and/or stability of RNA
2830/46	. elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

2830/48	. regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
2830/50	. regulating RNA stability, not being an intron, e.g. poly A signal
2830/52	. encoding ribozyme for self-inactivation
2830/55	. from bacteria
2830/60	. from viruses
2830/65	. from plants
2830/70	. from fungi
2830/702	. . yeast
2830/704	. . . S. cerevisiae
2830/706	. . . S. pombe
2830/708	. . . C. albicans
2830/75	. from invertebrates
2830/80	. from vertebrates
2830/85	. . mammalian
2830/90	. . avian

#### **2840/00 Vectors comprising a special translation-regulating system**

2840/002	. controllable or inducible
2840/005	. cell cycle specific
2840/007	. cell or tissue specific
2840/10	. regulates levels of translation
2840/102	. . inhibiting translation
2840/105	. . enhancing translation
2840/107	. . inhibiting translational read-through
2840/20	. translation of more than one cistron
2840/203	. . having an IRES
2840/206	. . . having multiple IRES
2840/44	. being a specific part of the splice mechanism, e.g. donor, acceptor
2840/445	. . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
2840/50	. utilisation of non-ATG initiation codon

#### **NOTE**

This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here

2840/55	. from bacteria
2840/60	. from viruses
2840/65	. from plants
2840/70	. from fungi
2840/702	. . yeast
2840/704	. . . S. cerevisiae
2840/706	. . . S. pombe
2840/708	. . . C. albicans
2840/75	. from invertebrates
2840/80	. from vertebrates
2840/85	. . mammalian
2840/90	. . avian

#### **2999/00 Further aspects of viruses or vectors not covered by the [C12N 2700/00](#) or [C12N 2800/00](#) series**

#### **NOTES**

1. This group is for classification of patent and non-patent literature documents.
2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.

## C12N

- 2999/002 . Adverse teaching
- 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals